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Strict Liability in the Manufacture of
Pharmaceuticals: The Halcion Homicide
Martin]. MacNeill*
l.

INTRODUCTION

In one of the first cases of its type, a woman from southern Utah
and her dead mother's estate brought suit 1 for negligence and wrongful
death against Upjohn, the maker of Halcion, the world's most prescribed sleeping pilt.2 The litigation is unique in that a user of Halcion,
who admitted to killing her mother, sued the drug company for civil
damages over the death.
On June 19, 1988, the fifty-eight-year-old plaintiff, Ilo
Grundberg, without apparent provocation, shot her eighty-two-year-old
mother eight times in the head and neck. 3 Mrs. Grund berg was arrested and charged with one count of second-degree murder. 4 As her
primary defense, Grundberg argued that she suffered from an acute
addiction to prescribed medication and that, at the time of her mother's
death, Grundberg was temporarily insane due to a severe case of "Halcion intoxication." 11 On February 8, 1989, after hearing initial testimony, Utah's Fifth District Court Judge J. Philip Eves dismissed all
charges against Grundberg, ruling that the killing was a result of her
addiction. 6
* B.S. 1975, St. Martin's College; D.O. 1983, College of Osteopathic Medicine of the Pacific; J.D. 1990, Brigham Young University, J. Reuben Clark Law School. This paper was
awarded first place in the American Bar Association Tort and Personal Injury 1990 Writing
Competition.
I. Grundberg v. Upjohn Co., No. 89-C-274-W (D. Utah filed Mar. 24, 1989). The suit,
however, has been settled. See Upjohn Settles Product Liability Suit Alleging Drug Led Woman
to Shoot Mother, 6 Toxics L. Rep. (BNA) 333-34 (Aug. 14, 1991) (terms are confidential). Two
Halcion class action suits are pending against Upjohn in the Southern District of Ohio: Wilson v.
Upjohn, No. C-1-89-346 (S.D. Ohio filed May 8, 1989) and Farris v. Upjohn Co., No. C-1-89553 (S.D. Ohio filed Aug. 14, 1989).
2. NAT'L L.J., Oct. 17, 1989 (LEXIS, Nexis, Omni File) ("The drug is the most widely
used sleep medicine and is currently sold in more than 75 ~ountries.").
3. United Press Int'l, Feb. 7, 1989 (LEXIS, Nexis, Omni file).
4. United Press Int'l, Mar. 25, 1989 (LEXIS, Nexis, Omni file).
5. Drugmaker Sued in Shooting Death, Chicago Tribune, March 26, 1989, at 14 (LEXIS,
Nexis, Omni file).
6. Blum, NAT'L L.J., Suit Blames Sleeping Pill For Murder, Apr. 10, 1989, at 9 (LEXIS,
Nexis, Omni file); United Press lnt'l, supra note 3 ("involuntary intoxication is a viable defense
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In filing the civil suit against Upjohn, Grundberg and her
mother's estate argued that "the drug Halcion (triazolam) was unreasonably dangerous, unsafe for its intended use and defective because of
its tendency to cause intoxication in the user, when used properly and
according to the advice and directions supplied by the defendant
[Upjohn]." 7 The plaintiffs further claimed that "[t]hese side effects, if
not promptly discovered and treated, can lead to personal injury and
death to the user and others in contact with the user." 8
The lawsuit sought damages for Mrs. Grundberg's "personal injuries, physical and mental pain and suffering, emotional distress, false
imprisonment, expenses and attorney's fees." 8 The decedent's estate
also sought to recover compensatory and punitive damages for the
wrongful death of Mrs. Grundberg's mother along with funeral and
burial expenses. 10 Mrs. Grundberg and her dead mother's estate argued that Upjohn, as the manufacturer, knew or should have known of
the drug's potential dangers. 11 Furthermore, the suit contended that
U pjohn marketed Hal cion at an excessive dosage. 12 This "excessive
dose was consumed by plaintiff Ilo Marie Grundberg, proximately
causing injury and damage to the plaintiff . . . as well as proximately
causing the wrongful death of her mother . . . ." 13 The suit claimed
that U pjohn was strictly liable for the alleged product defect. 14
The concept of strict liability eliminates the need to prove negligence for an injury caused by a defective product. 111 However, policy
[in the Grundberg case].").
7. Plaintiffs' Complaint at 5-6, Grundberg v. Upjohn Co., No. 89-C-274-W (filed Mar. 24,
1989).
8. ld. at 6.
9. ld. at 15.
10. !d. at 18.
11. !d. at 6.
12. !d. at 7 (Upjohn "manufactured, distributed, and sold the drug Halcion . . . in a dangerous, excessive dose, far beyond any reasonable and responsible margin of safety . . . . ").
It is interesting to note that in October 1987, the Federal Drug Administration lowered the
dosage recommended on the drug's label. Arieff, Bizarre Side-Effects Trigger Review of Popular
Sleeping Pill, Reuter Libr. Rep., Sept. 19, 1989 (LEXIS, Nexis, Omni file). The Physician's
Desk Reference of 1990 has also eliminated the 0. 5mg dosing suggestions. Prior to 1989 the recommendation of the manufacturer was for 0.5mg per night. Compare PHYSICIAN's DESK REFERENCE 2127-28 (42d ed. 1988) with PHYSICIAN'S DESK REFERENCE 2226-28 (44th ed. 1990). Unless otherwise noted, all references to the PDR will be to the 42nd edition of the Physician's Desk
Reference published in 1988.
13. Plaintiffs' Complaint at 7.
14. ld. at 12 (Upjohn "was liable to the plaintiffs under strict liability for the injurious
consequesces to the [plaintiffs] proximately caused by the manufacture, sale and use of the product
Halcion . . . . ").
15. Greenman v. Yuba Power Prod., 59 Cal. 2d 57, 377 P.2d 897, 27 Cal. Rptr. 697 (1963)
(Manufacturers should be strictly liable for products placed in the marketplace, knowing the product will not be further inspected, and possibly cause injury); Restatement (Second) of Torts §

69]

THE HALCION HOMICIDE

71

interests have shaped the unique nature of pharmaceutical case law to
provide multiple exceptions to the standard rules of strict liability.
Some of the exceptions favor plaintiffs. 18 In such cases, manufacturer
liability is easier to prove and is often decided with minimal evidence. 17
Other exceptions favor the defendants in drug-related litigation. The
most notable exception is comment k to § 402A of the Restatement
(Second) of Torts. 18 Comment k distinguishes some pharmaceuticals
from most other manufactured products by stating that the manufacturer is not held liable for injury from drugs which are seen as unavoidably unsafe. 19 Use of these drugs is seen as justified, even with the
apparent medical risks. 2 ° Certain products are unavoidably dangerous
and are incapable of being made safe when manufactured properly.
Presently, a majority of courts agree with the Restatement's view and
find some drugs dangerous by nature, but it is unclear which drugs are
unavoidably unsafe. 21
Pharmaceuticals are treated differently by the courts than other
402A (1) (1965) provides:
One who sells any products in a defective condition unreasonably dangerous to the user
or consumer or to his property is subject to liability for physical harm thereby caused
. . . if (a) the seller is engaged in the business of selling such a product, and (b) it is
expected to and does reach the user or consumer without substantial change in the
condition in which it is sold.
16. See Comment, DES and a Proposed Theory of Enterprise Liability, 46 FoRDHAM L.
REv. 963 (1978).
17. See Wells v. Ortho Pharmaceutical Corp., 788 F.2d 741 (11th Cir. 1986), cert. denied,
479 U.S. 950 (1986) (A multimillion dollar settlement against the manufacturer of a spermicidal
jelly without significant scientific proof of the teratogenic effects of the jelly).
18. The Restatement defines unavoidably unsafe products as products:
which, in the present state of human knowledge, are quite incapable of being made safe
for their intended and ordinary use. These are especially common in the field of
drugs. . . . Such a product, properly prepared, and accompanied by proper directions
and warning, is not defective, nor is it unreasonably dangerous.
RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965).
19. /d.
20. Comment k to §402A further provides:
The same is true of many other drugs, vaccines, and the like, many of which for this
very reason cannot legally be sold except to physicians, or under the prescription of a
physician. It is also true in particular of many new or experimental drugs as to which,
because of lack of time and opportunity for sufficient medical experience, there can no
be assurance of safety, or perhaps even of purity of ingredients, but such experience as
there is justifies the marketing and use of the drug notwithstanding a medically recognizable risk. The seller of such products, again with the qualification that they are
properly prepared and marketed, and proper warning is given, where the situation calls
for it, is not to be held strictly liable for unfortunate consequences attending their use,
merely because he has undertaken to supply the public with an apparently useful and
desirable product, attended with a known but apparently reasonable risk.
/d.
21. See, e.g., McElhaney v. Eli Lilly & Co., 575 F. Supp. 228 (D.S.D. 1983).
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manufactured products. 11 One reason for this different treatment is the
interaction which occurs between the body of the patient and the drug's
chemical compound. When a drug is ingested, the response of an individual patient is difficult to predict. Every effect and each adverse reaction is unique. Frequently, the response to the chemical is more dependant on the individual's physiology than on product design. Therefore,
a safely designed drug for every situation or every person may be illusory. Some commentators consider the pharmaceutical industry sufficiently unique to be categorized separately from all other forms of
product liability. 18 Others believe the drug manufacturer should be held
to the same form of strict liability as are other industries. 24 Still others
contend that the pharmaceutical companies should be strictly liable for
their products, but define the role of liability differently, usually holding manufacturers to a lesser standard. 211
This article discusses strict liability as it applies to pharmaceutical
manufacturers and views Halcion as an example of a potentially defective product. Part II provides a brief survey of the pharmaceutical industry, including an evaluation of the product Halcion. Part III deals
with the role of government regulatory efforts. Part IV evaluates strict
tort liability as it applies to the pharmaceutical industry. It also discusses manufacturing and design defects, the role of adequate warnings
of potentially adverse drug reactions, causation, parties, defenses and
damages. The article concludes that drug manufacturer liability should
be limited for unknown and/or rare adverse reactions, and thus Upjohn
should not be found liable in the Grundberg case.

II.
A.

PHARMACEUTICAL BACKGROUND

Drug Industry

The drug industry in America has changed dramatically since the
1930s and 1940s. Early pharmaceutical companies generally produced
22. See infra notes 81-82 and accompanying text.
23. See, e.g., Scott, Medical Product and Drug Causation: How to Prove It and Defend
Against It, 56 DEF. CouNs. J. 270 (1989); Leighton, Introduction to the Symposium on Chemical
and Food Product Liability, 41 Fooo DRUG CosM. L.J. 385 (1986); Schwartz, Unavoidably
Unsafe Products, 42 WASH. & LEE L. REV. 1139 (1985).
24. McClellan, Drug Induced Injury, 25 WAYNE L. REV. I (1978); Maldonado, Strict Liability and Informed Consent: 'Don't Say I Didn't Tell You So,' 9 AKRON L. REV. 609 (1976);
Merrill, Compensation for Prescription Drug Injuries, 59 VA. L. REV. I (1973); Keeton, Products Liability-Drugs and Cosmetics, 25 VAND. L. REV. 131 (1972).
25. Britain, Product Honesty Is the Best Policy: A Comparison of Doctors' and Manufactur-

ers' Duty to Disclose Drug Risks and the Importance of Consumer Expectations in Determining
Product Defect, 79 Nw. U.L. REv. 342 (1984); Fink, Education in Pharmacy and Law, 26 J.
LEGAL Eouc. 528, 538 (1974).
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a complete line of medication to serve the pharmacist's needs. 26 These
companies spent very little money on research, development, or advertisement. Customarily, the basic drug ingredients constituted seventyfive percent of corporate expenditures. 27
By the time Halcion was developed in the 1980s, a major transformation had occurred within the pharmaceutical industry. The impetus
for this change was the increasing efficacy of drugs. 28 In the early part
of the century, even with hundreds of compounds on the market, few
"cures" could be credited to pharmaceuticals. 29 Most drugs sold were
for supportive care and did little to affect the course of illness directly.
However, by the late 1940s and early 1950s, drugs took the offensive
against disease. 30 Penicillin and other broad spectrum antibiotics heralded a new age, in which medicine could directly attack foreign cells
without harming the host. Because most drugs are effective against only
one or two conditions, hundreds of drugs are sold. In the United States,
the number of physiologically active compounds number over one thousand. 31 These compounds in turn are mixed with other compounds
which produce hundreds of thousands of products. 32
26. Many of the pharmaceutical firms are dependant on one to five of their products for the
bulk of their profit. A company may produce 50 to 300 drugs but up to SOo/o of their profit may be
produced by the one or two most profitable drugs. See Staudt, Determining and Evaluating the
Promotional Mix, MoDERN MEDICINE ToPICS 8 (July 1957).
Few products in this field have any definite assurance of future share in the market. For
every I 00 products introduced only 8 will be among the best prescription sellers, another 7 to I 0
will pay their own way, and over 80 will fail. Up to 90% of the total company profit may be from
the manufacture of the five top selling drugs. /d.
27. For a competent evaluation of the history of the drug industry, see E. AcKERKNECHT,
THERAPEUTICS FROM THE PRIMITIVES TO THE 20TH CENTURY (1973).
28. Another major change that occurred in the pharmaceutical industry was the development
of the transnational corporations. Global profit, rather than regional needs, would affect development, research, and marketing strategies. With these and other changes occurring, it became clear
that more regulatory efforts would be needed to protect the citizenry. /d. at 144-45.
29. The few exceptions include Salvarsan (a cure for syphilis in Germany) in 1910, sulfonamides (antibiotics in Germany and France) in the late 1930s, and penicillin (an antibiotic in
England) in the mid-1940s. /d. at 145.
30. Further advances in antibiotics (broad spectrum penicillins, tetracycline, erythromycin
and later the cephalosporins), tranquilizers, steroids, oral contraceptives, cardiac active agents,
diabetic medicines, and diuretics all were developed and first utilized in the 1950s and 1960s. /d.
at 30.
31. The drug market is broken down into over the counter (OTC) and prescription drugs.
OTCs are those that are sold directly to the consumer without the need for physician contact. The
drugs within this category vary from country to country. Prescription drugs are those that require
an order of a physician prior to purchase. This category makes up the largest share of the overall
dollar value of drug sales worldwide. U.N. INDUSTRIAL DEVELOPMENT ORGANIZATION, THE
GROWTH OF THE PHARMACEUTICAL INDUSTRY IN DEVELOPING CoUNTRIES: PROBLEMS AND
PROSPECTS, at 23, U.N. Doc. ID/204, U.N. Sales No. E.78.11.B.4 (1978).
32. While no one knows exactly how many drugs are available on the ethical drug market, it
is estimated that between I 0,000 and 25,000 different drugs are available for sale. Halberstrom,
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Upjohn developed Halcion in the 1970s and first marketed it to
Americans in 1983. 88 In the following six years, doctors wrote fortythree million prescriptions for the drug within the United States. 84

B.

Pharmacology of Halcion

Prior to the Grundberg controversy, Halcion was the nation's most
prescribed hypnotic agent. 811 The hypnotics (i.e., sleeping pills) are used
to depress the central nervous system which causes sleep. 86 This form
of sedative is usually reserved for mild to moderate short-term insomnia.87 Benzodiazepines, such as Halcion, are considered safe and effective in the treatment of acute insomnia. 88

1.

Halcion action

Halcion is the brand name for triazolam, a short-acting hypnotic
with a standard plasma half-life of two-and-one half hours. 39 The average patient's blood level of Halcion will peak one hour and fifteen minutes following ingestion of a single dose. 4° Full excretion, on the average, occurs quickly-within a range of eighty minutes to six hours. 41
Halcion leaves the body rapidly which prevents the "hangover" effect
Too Many Drugsr F. ON MED., Mar. 1979, at 3.
33. Woman Sues, Saying Sleeping Pill Caused Her to Shoot Mother, Reuters, Mar. 24, 1989
(LEX IS, Nexis, Omni file); see also Arieff, Regulators Worried by Side Effects of Popular Sleeping Pill, Reuters, Sept. 22, 1989, (LEXIS, Nexis, Omni file) (Hacion was first marketed in 1977
in Belgium). /d.
34. Scrip, U.S. F.D.A. Committee-No Halcion Alarm, WoRLD PHARM. NEws I (Oct. 6,
1989).
35. Sigelman, Halcion: Waking Up to the Dangers of a Sleeping Pill, TRIAL Nov. 1989, at
38 (1989) (Halcion is the most prescribed pharmaceutical in the America with a 46% share of the
sleeping pill market in 1987). Hypnotic agents are those which are used to produce sleep. Other
common drugs in this category include Dalmane and Restoril. /d.
36. Sleep induced by hypnotics differs from normal physiological sleep in a number of ways
including reduction of REM (Rapid Eye Movement) sleep and reduction of stage IV sleep.
AMERICAN MEDICAL ASSOCIATION DIVISION OF DRUGS AND TOXICOLOGY, DRUG EVALUATIONS SUBSCRIPTION, § 3, PSYCHOPHARMACOLOGIC DRUGS 1:17 (1990).
37. Chronic insomnia is treated using methods which attempt to correct the cause of the
insomnia rather than using chemical depressants such as the hypnotics. Chronic insomnia is often
due to physical pathology, including pain (e.g., arthritis, angina, ulcer, etc.), congestive heart failure, or respiratory disease. Other causes of insomnia may include schizophrenia, depression, anxiety, or phobias. MERCK, SHARP & DOHME RESEARCH LABORATORIES, THE MERCK MANUAL
OF DIAGNOSIS AND THERAPY 1321-22 (14th ed. 1982).
38. AMERICAN MEDICAL ASSOCIATION DEPARTMENT OF DRUGS, A.M.A. DRUG EVALUATIONS 140 (4th. ed. !980).
39. This information is available in the product insert, a copy of which is found in Appendix
A.
40. E.A. Swingard, Chapter 57: Sedatives and Hypothics, in REMINGTON's PHARMACEUTICAL SCIENCES 1064 (17th ed. 1985).
41. Halcion leaves the body via the urinary tract. See sample product insert in Appendix A.
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often seen with other drugs. 42
Most patients achieve the desired drowsiness within thirty minutes
of ingestion and a full, deep sleep within one hour. Due to its excretory
status (i.e., elimination from the body in most cases in less than six
hours), most patients do not suffer the daytime drowsiness present with
other sedatives. With its fast onset of action and its rapid rate of excretion, Halcion quickly became the sleeping pill of the 1980s for many
Americans. 43
Halcion assists sleep in a number of ways. It increases the speed of
the onset of sleep, increases the total sleep period, and decreases the
frequency of awakenings during the night. The drug's beneficial effects
diminish rapidly with long-term administration. Due to this loss of efficacy, Upjohn recommends discontinuing use after one month."

2.

Adverse Halcion reactions

Adverse reactions are the unwanted interactions between a drug
and a recipient's physiology. Multiple forms of adverse reactions are
possible with any allergen. 46 H ypersensitivity 46 or allergic reactions, 47
drug interactions, excessive amounts of the desired effect, unavoidable
side effects, and activation of physical illness are a few of the adverse
reactions possible with any drug. Wherever possible, a manufacturer
should seek to discover and eliminate these unwanted side-effects. Adverse reactions to drugs remain one of the major causes of hospitalization, illness, and death in the nation. Some authors believe that over
one hundred and forty thousand deaths per year are caused by adverse
drug reactions in the United States. 48 A product, however, that is
highly beneficial to millions of patients may be deadly to a few. Most
commentators agree that a prescription drug will not be considered defective if an unusually sensitive user develops an adverse reaction. 49
a. Known adverse reactions. Pharmaceutical manufacturers are
required to warn adequately of known dangers in the administration of
42. Halcion's lack of carry-over sleepiness is utilized as part of its advertisement campaign.

See Prager, An American Nightmare: Previous Suits Against Drug Companies Have Resulted in
the Loss to Americans of Useful Drugs, CoRTLANDT F., 1989.
43. Sigelman, supra note 35, at 38 (1989).
44. PHYSICIAN'S DESK REFERENCE 2127-28 (42d ed. 1988).
45. An allergen is any foreign substance capable of eliciting an allergic or hypersensitive
response. MERCK, SHARP & DOHME RESEARCH LABORATORIES, supra note 37, at 266.
46. Hypersensitivity is an exaggerated response to an allergen. ld. at 270.
47. An allergic reaction is a hypersensitivity to a allergen that builds with repeat exposure.
/d. at 265-287.
48. TALLY & LAVENTURIER, DRUG-INDUCED ILLNESS, 229 J. A.M.A. 1043 (1974).
49. E.g., RESTATEMENT (SECOND) OF TORTS§ 402A comment c (1965).
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their product. 60 Halcion had multiple warnings of known dangers listed
in the Physician Desk Reference (PDR) prior to the Grundberg incident. 61 Some of the dangers which had been seen in patient trials at
normal dosage levels included: fetal abnormalities in pregnant women,
drowsiness, dizziness, light-headedness, and impaired coordination. 62
Other studies report amnesia, nervousness, nausea, vomiting, tachycardia, cramps, and depression. 63 In addition, visual disturbances, confusional states, euphoria, diarrhea, dry mouth, nightmares, and insomnia
have been noted. Upjohn also reported ringing in the ears, weakness,
congestion, hepatic failure, anorexia, clouding of consciousness, slurred
speech, and jaundice. 64 Further side-effects reported in the literature
included itching, menstrual irregularities, incontinence, urinary retention, and agitation. Furthermore, spasticity, hallucinations, aggressiveness, sleepwalking, changes in libido, and death were occasionally
noted. 66
b. Unknown adverse reactions. Possibly more serious than known
side-effects are those which are undiscovered prior to an adverse reaction in the ultimate consumer. While no national consensus exists on
the question, some courts consider an undiscovered side-effect as a de50. See, id. at comment j (1965).
51. PHYSICIAN'S DESK REFERENCE, supra note 44, at 2!27-28.
52. /d.
53. "In addition to the relatively common (ie, I% or greater) untoward events enumerated
above, the following adverse events have been reported less frequently (ie, 0.9-0.5%): euphoria,
tachycardia, tiredness, confusional states/memory impairment, cramps/pain, depression, visual
disturbances." !d. at 2128.
54. Rare (ie, less than O.So/o) adverse reactions included constipation, taste alterations,
diarrhea, dry mouth, dermatitis/allergy, dreaming/nightmares, insomnia, paresthesia,
tinnitus, dysesthesia, weakness, congestion, death from hepatic failure in a patient receiving diuretic drugs.
In addition to these untoward events for which estimates of incidence are available,
the following adverse events have been reported in association with the use of HALCION and other benzodiazepines: amnestic symptoms (anterograde amnesia with appropriate or inappropriate behavior), confusional states (disorientation, derealization,
depersonalization, and/or clouding of consciousness), dystonia, anorexia, fatigue, sedation, slurred speech, jaundice, pruritus, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention. Other factors may contribute to some of
these reactions, eg, concomitant intake of alcohol or other drugs, sleep deprivation, an
abnormal premorbid state, etc.
Other events reported include: paradoxical reactions such as stimulation, an agitational state (restlessness, irritability and excitation), increased muscle spasticity, sleep
disturbances, hallucinations, aggressiveness, falling, somnambulism, inappropriate behavior and other adverse behavioral effects. Should these occur, use of the drug should
be discontinued.
PHYSICIAN'S DESK REFERENCE, supra note 44, at 2128.
55. Precautions on the product insert include the following: "Some side effects reported in
association with the use of HALCION appear to be dose related. These include drowsiness, dizziness, lightheadedness, and amnesia." See Halcion Product Insert, Appendix A.
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feet and cmpose the same strict liability as with other defects. 116 Others
look to comment k of § 402A and insulate drugs from standard product
liability .117

III.

GovERNMENT

REGULATION

OF

THE

PHARMACEUTICAL

INDUSTRY

A.

History of Government Regulation

The first attempt at government regulation of the pharmaceutical
industry was the passage of the Federal (Pure) Food and Drugs Act of
1906. 118 The Act addressed concerns about drug safety and improper
advertising practices within the industry. 119 For the first time, the full
disclosure of a drug's composition was required. 60
Congress further strengthened medication regulation by passing
the Food, Drug and Cosmetic Act of 1938,61 requiring proof of safety
prior to marketing new drugs. Prescriptions were to be used for the
majority of drugs and public access to thousands of products was to be
restricted. The Food and Drug Administration (FDA) was authorized
to police the market and set policy for the sale and distribution of new
drugs.
Until the Kefauver-Harris Amendments to the Food, Drug and
Cosmetic Act were established in 1962,62 drug manufacturers were not
required to prove their drug's efficacy. Due to the widespread concern
of drug safety caused by the thalidomide tragedy, 63 the KefauverBarris Amendments imposed strict guidelines which led to the removal
56. See, e.g., Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981).
57. See, e.g., Johnson v. American Cyanamid Co., 239 Kan. 279, 285, 718 P.2d 1318, 1323
(1986).
58. Ch. 3915, Pub. L. No. 59-384, 34 Stat. 768 (codified as amended in scattered sections of
21 U.S.C. (1982)). This legislation was influenced by the work of the Muckrakers. The Muckrakers were authors who believed government should protect workers from big business. One such
author, Upton Sinclair, heavily influenced passage of the Federal Pure Food and Drugs Act. See
generally A. CRAVEN AND W. jOHNSON, THE UNITED STATES: EXPERIMENT IN DEMOCRACY
519-21 (1947).
59. § I, 34 Stat. 768 ("[l]t shall be unlawful for any person to manufacture . . . any article
of food or drug which is adulterated or misbranded . . . . "). See generally J. H. YouNG, THE
TOADSTOOL MILLIONAIRES: A SOCIAL HISTORY OF PATENT MEDICINES IN AMERICA BEFORE
FEDERAL REGULATION 205-44 (1972).
60. § 8, 34 Stat. 770.
61. Ch. 675, Pub. L. 75-717, 52 Stat. 1040.
62. Drug Amendments of 1962, § 102, Pub. L. 87-781, 76 Stat. 781.
63. Thalidomide, a medication given to thousands of pregnant women in Europe, caused
hundreds of severe birth defects. This drug was in the process of gaining access into the American
market when the European findings were brought to the attention of the public. Sherman &
Strauss, Thalidomide: A Twenty-Five Year Perspective, 41 FooD DRUG CosM. L.J. 458, 458
(1986).
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of seven thousand drugs from the market and a stricter labeling of over
fifteen hundred others. 84

B.

The Current Regulatory Scheme

Since that time, the FDA has experienced great difficulty identifying and communicating the hazards of prescription drugs. 811 The FDA
must verify the safety and efficacy of new drugs before approving them
for human use. The agency requires a lengthy experimental protocol
before a drug may be marketed. Thereafter, the manufacturer must periodically review the drug's safety and efficacy in the population at
large.
One of the potentially serious difficulties with the FDA's system is
the agency's dependence on manufacturers for adverse reaction data. It
is the manufacturer's responsibility to perform all pre-marketing tests
and collect all post-marketing results. In reporting adverse reactions,
drug companies have been caught falsifying tests and lying. 88 The most
recent cases have dealt with fraud within the generic drug industry. 87
Adverse reaction data collected by Upjohn led at least one foreign
government to deny further marketing of Halcion. 88 The FDA has not
placed similar restrictions on sales in the United States. Furthermore,
on September 22, 1989, the FDA's Psychopharmacological Drugs Advisory Committee concluded that Halcion posed "no public health risk
to patients in the U.S." 89 The committee, however, did recommend
modifying the label to warn of the "increased incidence of anterograde
amnesia compared with other hypnotics." 70
64. See Janssen, Outline of the History of U.S. Drug Regulation, 36 FooD DRUG CosM.
L.J. 420, 439 (1981).
65. See generally Safir, FDA Regulations and Product Liability, 36 FooD DRUG CosM.
L.J. 478 (1981); Ryan v. Eli Lilly & Co., 514 F. Supp. 1004 (D.S.C. 1981); Henteleff, Interrelationships of FDA Laws and Regulations with Products Liability Issues, 32 Bus. LAw. 1029
(1977).
66. See, e.g., Blum, High Stakes: Wonder Drugs Are the Focus of Criminal, Civil Actions;
Patients Sue Makers of Psychotropic Drugs, Nat'! L.J., Oct. 22, 1990, at I (LEXIS, Nexis, Omni
file). In 1985, Eli Lily Company plead guilty to criminal charges and paid $25,000 in fines for
failing to report four deaths and six illnesses that occurred in Europe related to use of its drug,
Oraflex. Eli Lily was required to withdraw the drug from the United States market. /d.
67. For example, the maker of the generic form of the drug Dyazide was accused of falsifying test data and of paying bribes to FDA inspectors. Strickland & Bolar, A Drug Company
Under Siege, N.Y. Times, Oct. 15, 1989, § 12LI, at I, col. 3 (LEXIS, Nexis, Omni file).
68. See letter from Lawrence C. Hoff, President and Chief Operating Officer of Upjohn to
John Sias, President of ABC, Inc. (Feb. 24, 1989) in Appendix B.
69. Scrip, supra note 34.
70. /d.

THE HALCION HOMICIDE

69)

1.

79

Drug testing

In the United States, bringing a new drug to the point-of-sale to
the public is a long and complex process. By the time a new medicine
becomes available for general use, it has been tested on both animals
and humans under controlled protocol set out by the FDA. 71
The FDA's protocol for testing drugs only partially shields drug
manufacturers from lawsuits. The manufacturers are protected from liability for injuries only if they strictly follow FDA procedure. 72 Within
the FDA guidelines a drug manufacturer has significant leeway in deciding the extent of product testing. Moreover, the manufacturer has
almost total discretion to determine what type of experimentation and
research is necessary. But in exercising this discretion, the manufacturer takes upon itself additional responsibility and increased liability
exposure. For example, the duty to test is a continuing one. The manufacturer is liable if it fails to test adequately all aspects of drug usage. A
drug used by consumers on a long-term basis may be deemed insufficiently tested if the only study performed was to evaluate short-term
effect. 73

2.

Reporting adverse reactions

Continued evaluation of a product after approval by the FDA is a
vital part of the regulatory process. Many pathologies become present
71. 21 C.F.R. § 314.1 (1990). This process occurs as follows:
(I) Discovery phase: Basic research leads to the synthesis of a new chemical. This phase
includes early studies of the compound's chemical properties.
(2) Pre-clinical animal testing: A short-term animal toxicity testing for evidence of
safety. Tests required at this stage include pharmacodynamics, endocrinology, metabolism,
toxicology, and teratology studies.
(3) Investigational New Drug (IND) filing: A request is made for authorization to begin
human testing.
(4) Phase I human testing: Dosage is administered to healthy volunteers for evidence of
toxicity in humans.
(5) Phase II human testing: Dosage is administered to humans with a particular pathological condition.
(6) Phase III human testing: Large-scale tests on humans are performed over a longer
period to uncover unanticipated side-effects.
(7) Long-term animal studies: To determine the effects of prolonged exposures and the
effects on subsequent generations.
(8) New drug application: Application for commercial marketing.
72. Ryan v. Eli Lilly & Co., 514 F. Supp. 1004 (D.S.C. 1981) (Injury sustained by a manufacturer's compliance with FDA protocol shields the company from litigation). But see Stromsodt
v. Parke-Davis & Co., 257 F. Supp. 991 (D.N.D. 1966), affd, 411 F.2d 1390 (8th Cir. 1969)
(Compliance with FDA testing protocol does not shield manufacturer from liability if adequate
testing is not performed).
73. Hoffman v. Sterling Drug, 485 F.2d 132 (3d Cir. 1973) (Manufacturer found liable for
inadequate testing of a drug which, if used over a long term, led to retinal damage).
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only after years of drug use in the general population. Indeed, adverse
reaction reporting has increased significantly over the past few years."
In 1985, the FDA formulated new post-marketing surveillance requirements which will better accumulate data and utilize discovered information on adverse reactions nationwide. 711 Manufacturers are now required to report within fifteen days any adverse drug reaction which
leads to death, hospitalization, permanent disability, or need for drug
therapy. Less virulent reactions must be reported "promptly," but the
manufacturer is given a longer period to do so. 76 Manufacturers that do
not comply with the reporting requirements are subject to increased
liability. 77
Without this government regulation, drug companies would have
neither the incentive nor the ability to police their products in the market. Studies have shown that adverse reactions are grossly underreported by the medical establishment. 78 The reasons for not reporting
adverse reactions are numerous. First is the inability to differentiate the
adverse reaction from the symptoms of disease. Second is the general
reluctance of doctors and patients to report problems. 79 Even after a
drug has been proven harmful, the physician may still not wish to report adverse reactions because of fear of malpractice liability. For example, in the mid-1960s, it was estimated that seventeen hundred
deaths occurred due to the widespread use of an aerosol asthma medication. However, only six deaths were officially reported as caused by
this medication. 80
IV.
A.

STRICT LIABILITY AND PHARMACEUTICALS

Strict Liability as Applied to Pharmaceuticals

Most courts categorize rules of liability which apply to prescription drugs differently than rules for other products. Some courts have
held that the rules of strict liability should not apply to some drugs. 81
74. There were over 37,000 reports of adverse reactions in 1985. Faich, Knapp, Dreis &
Turner, National Adverse Drug Reaction Surveillance: 1985, 257 J. A.M.A. 2068, 2068 (1987).
75. See Sills, Faich, Milstein & Turner, Postmarketing Reporting of ADRs to FDA: ,-\n
Overview of the 1985 Guideline, 20 DRUG INFO. J. 150 (1986).
76. 21 C.F.R. § 314.80 (c)(l) (1990).
77. Jd. at (k).
78. Faich, Adverse Drug Experience Reporting and Product Liability, 41 FooD DRUG
CosM. L.J. 444 (1986).
79. Merrill, Compensation for Prescription Drug Injuries, 59 VA. L. REv. 1, 50-68 (1973).
80. H. TEFF & C. MUNRO, THALIDOMIDE: THE LEGAL AFTERMATH 109 (1976).
81. See, e.g., Johnson v. American Cyanamid Co., 239 Kan. 279, 285, 718 P.2d 1318, 1323
(1986) ("Orimune, the Sabin-type vaccine, is an 'apparently useful and desirable product, attended with a known but apparently reasonable risk as a matter of law.'" (quoting RESTATEMENT (SECOND) OF TORTS§ 402A comment k (1965))).
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Other courts apply a limited form of strict liability with less stringent
rules applied to drugs. Still other courts do not differentiate between
drugs and other manufactured products. 82
The Restatement (Second) of Torts § 402A comment k views some
drugs as "incapable of being made safe." For example, "the vaccine for
the Pasteur treatment of rabies" often "leads to very serious and damaging consequences when it is injected." Such a drug is "properly prepared, and accompanied by proper directions and warning, is not defective, nor is it unreasonably dangerous." 83 Comment k does not seek to
prevent all suits against drug manufacturers. While it protects drug
manufacturers against liability for design defects, it does not immunize
them against suits for manufacturing defects or inadequate warnings. 84
One recent case supported comment k's liability limitation. In
Brown v. Superior Court, 8 1l the California Supreme Court discussed
the standards of strict liability and found that manufacturers of unavoidably unsafe drugs should not be held to this same level of responsibility. The court reasoned that subjecting a drug manufacturer to
strict liability for design defects would decrease the availability of
needed drugs to the public. 86 Even with the potential risks, the court
held that all drug design defects should be protected as stated in comment k because public policy favors the development and marketing of
new drugs. 87
When a defective product induces property damage or physical
harm in a consumer, the liability for the loss shifts to the manufacturer
from the consumer. As Justice Roger]. Traynor of the California Supreme Court initially stated: "A manufacturer is strictly liable in tort
when an article he places on the market, knowing that it is to be used
without inspection for defects, proves to have a defect that causes injury
"88

Multiple policy considerations are behind the adoption of strict liability in torts. Some of these include compensation or spreading of the
loss between all consumers of a product, deterrence, encouraging useful
82. See, e.g., Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981) (Drug
design defects should be subject to the same strict liability standards as other products).
83. RESTATEMENT (SECOND) OF TORTS § 402A comment k (1965) (emphasis in original).
84. Id.
85. 44 Cal. 3d 1049, 751 P.2d 470, 245 Cal. Rptr. 412 (1988).
86. Id. at 1063, 751 P.2d at 478, 245 Cal. Rptr. at 420.
87. ld. at 1064, 751 P.2d at 479, 245 Cal. Rptr. at 421.
88. See Greenman v. Yuba Power Prod., 59 Cal. 2d 57, 62, 377 P.2d 897, 900, 27 Cal. Rptr.
697, 700 (1963). The California Supreme Court was the first court to adopt strict tort liability as
a theory for recovery. Within one year of Greenman, the American Law Institute adopted RESTATEMENT (SECOND) OF ToRTS § 402A (1965), which was structured along the same lines as
the Traynor opinion.
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conduct by both parties to an action, protecting consumer expectations,
and improving the allocation of resources. 89
For the rules of strict liability in tort to apply to Upjohn as the
manufacturer of Halcion, the key analysis is whether the drug is and
was defective. Multiple approaches have been used by the courts in the
development of the concept of defectiveness.
One approach is the consumer expectation test 90 which weighs
whether a product is unreasonably dangerous beyond that contemplated
by the ordinary consumer. This test has fallen from favor in a majority
of courts because it relies upon the term "unreasonable" as a requirement of defectiveness. Reasonableness is a negligence concept. 91 If a
danger is one generally known to the ordinary consumer, then the
product is not per se defective. 92
Another approach is the risk/utility test. 93 This is a balancing test
between the risk of danger associated with a product and the utility of
the product to the consumer. It is the most used approach to determine
defectiveness. 94 The emphasis is on the safety of the product rather
than on the reasonable or unreasonable action of the manufacturer. 96
Some of the factors considered in a risk/utility analysis include the se89. For an excellent discussion of the policies underlying strict liability, see D. FISCHER &
W. POWERS jR., PRODUCTS LIABILITY: CASES AND MATERIALS 50-51 (1988).
90. RESTATEMENT (SECOND) OF TORTS § 402A comment g (1965). Comment g provides:
The rule stated in this Section applies only where the product is, at the time it leaves
the seller's hands, in a condition not contemplated by the ultimate consumer, which will
be unreasonably dangerous to him. The seller is not liable when he delivers the product
in a safe condition, and subsequent mishandling or other causes make it harmful by the
time it is consumed. The burden of proof that the product was in a defective condition
at the time that it left the hands of the particular seller is upon the injured plaintiff;
and unless evidence can be produced which will support the conclusion that it was then
defective, the burden is not sustained.
91. RESTATEMENT (SECOND) OF TORTS § 395 (1965). Section 395 provides:
A manufacturer who fails to exercise reasonable care in the manufacturer of a chattel
which, unless carefully made, he should recognize as involving an unreasonable risk of
causing physical harm to those who use it for a purpose for which the manufacturer
should expect it to be used . . . is subject to liability for physical harm caused to them
by its lawful use. . . .
92. /d. at § 402A comment i (1965) (emphasis added). Comment i provides:
The rule stated in this Section applies only where the defective condition of the product
makes it unreasonably dangerous to the user or consumer . . . . The article sold must
be dangerous to an extent beyond that which would be contemplated by the ordinary
consumer who purchases it, with the ordinary knowledge common to the community as
to its characteristics.
93. See, e.g., Boatland of Houston, Inc. v. Bailey, 609 S.W.2d 743, 746 (Tex. 1980) (A
product must be judged for defectiveness at the time of the harm and based on technology then
available).
94. See, e.g., Phillips v. Kimwood Mach. Co., 269 Or. 485, 525 P.2d 1033 (1974); Dosier v.
Wilcox-Crittendon Co., 45 Cal. App. 3d 74, 119 Cal. Rptr. 135 (1975).
95. See Britain, supra note 25.
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verity of the risk, the likelihood of harm, the benefits of the product,
and the feasibility of an alternative design. 96 Once a product is determined to be dangerous, the court then must balance the product's utility against its dangers. Many courts refuse to classify a drug as unreasonably dangerous if the drug's utility to mankind is viewed as greater
than the potential for injury to an individual. 97
Lastly, some jurisdictions offer an alternative test that utilizes a
bifurcated standard: either consumer expectation or risk/utility. 98 Use
of the disjunctive expands recovery potential for plaintiffs. 99

B.

Types of Defects

Halcion can be defective in three ways. First, there could be a
manufacturing defect which might cause one "batch" of the drug to
deviate from the norm. Second, a design defect could exist such as a
basic intrinsic flaw in the chemical design. Third, Upjohn could have
provided insufficient warning of the dangers of using its sleeping pill.

1.

Manufacturing defects

Manufacturing defects are those which deviate from the manufacturer's design or specifications and thus are different than the usual
product that "comes off the assembly line." 100 Manufacturing defects
are usually easy to identify because the products are flawed. Even
though the cause of the manufacturing defect is usually negligence, difficulty in proof requires a strict liability standard, without regard to the
manufacturer's reasonableness in protecting its process from error. 101
The consumer expectation test is utilized because the consumer expects
a product to be free of defects. 102
As an industry, pharmaceutical manufacturers have maintained a
good record of keeping manufacturing defects to a minimum. From
1966 to 1971, 1,935 drug recalls were ordered by the FDA for mistaken labelling, contamination, adulteration, or incorrect dosage. 103
96. Wade, On the Nature of Strict Tort Liability for Products, 44 Miss. L.J. 825, 829
(1973) (factors to consider in a risk/utility analysis).
97. See contra Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 19Bl).
98. Barker v. Lull Engineering Co., 20 Cal. 3d 413, 573 P.2d 443, 143 Cal. Rptr. 225,
(1978) (permitting the use of either the consumer expectation test or the risk/utility test).
99. D. FISCHER & W. POWERS jR., supra note 89, at 91.
100. Barker v. Lull Engineering Co., 20 Cal. 3d 413, 429, 573 P.2d 443, 459, 143 Cal.
Rptr. 225, 241 (1978).
101. D. FISCHER & W. PoWERS, jR., supra note 89, at 1.
102. See Britain, supra note 25.
103. M. SILVERMAN & P. LEE, PILLS, PROFITS AND PoLITICS 333 (1974).
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Apart from the sulfanilamide disaster/ 04 there have been few episodes
of death or disability due to manufacturing defects. 1011 There have been
none involving Halcion.

2.

Design defect

Whereas a manufacturing defect involves an isolated deviation
from the norm, a design defect involves the entire line of products. The
product is manufactured according to specifications but remains unreasonably dangerous for its intended use. 106 Difficulty in determining design defect arises when the courts attempt to define "reasonable
danger. " 107
If a design is found to be defective, then all of the products manufactured using that design will be defective. To determine if the initial
design of Halcion was defective requires jury evaluation. The jury will
be called upon to balance the utility of the drug's sedative effect against
its potential adverse reactions. 108 The evaluation of design defect by the
jury is based on a four-prong test: (1) feasibility of an alternative design (2) at the time of the manufacture which was (3) commercially
available and (4) would not destroy the product's productivity. 109 The
design of Halcion has not been shown to be defective and furthermore
has been cleared by the FDA for continued use by the public. 110
Some courts hold that the "FDA's decision of product marketabil104. A batch of sulfanilamide was improperly mixed with a lethal solvent causing the death
of many patients during the 1950s. J. Schnze, Governmental Control of Therapeutic Drugs: Intent, impact and issues, in THE PHARMACEUTICAL INDUSTRY 9-10 (C. Lindsay ed. 1978). For a
competent evaluation of the history of the drug industry, see G. PoRTER AND H. LIVESAY,
MERCHANTS AND MANUFACTURER: STUDIES IN THE CHANGING STRUCTURE OF NINETEENTH
CENTURY MARKETING (197! ).
105. /d.
106. Comment, Can a Prescription Drug be Defectively Designed?: Brochu v. Ortho Pharmaceutical Corp., 31 DE PAULL. REv. 247 (1981).
107. Birnbaum, Unmasking the Test for Design Defect: From Negligence [to Warranty} to
Strict Liability to Negligence, 33 VAND. L. REv. 593 (1980).
I 08. A product is defective in design if:
(I) the plaintiff proves that the product failed to perform as safely as an ordinary
consumer would expect when used in an intended and reasonably foreseeable manner,
or
(2) the plaintiff proves that the product's design proximately caused injury and the
defendant fails to prove . . . that on balance the benefits of the challenged design outweigh the risk of danger inherent in such design.
Barker v. Lull Engineering Co., 20 Cal. 3d 413, 426-27, 573 P.2d 443, 452, 143 Cal. Rptr. 225,
234 (1978); see also Britain, supra note 25, at 363-67.
109. Isaacs, Drug Regulation, Product Liability, and the Contraceptive Crunch: Choices
Are Dwindling, 8 J. OF LEG. MED. 533 (1987) (strict liability and duty to warn).
110. Scrip, supra note 34.
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ity disposes of the defect issue." 111 These courts conclude that if the
FDA disapproves a product, "the product must be considered unavoidably unsafe as a matter of law and thus outside the parameters of strict
liability for defective design." 112
Occasionally, the government accepts responsibility for drug defects. In 1976, the government statutorily accepted liability for any adverse reactions to the swine flu immunization program. 113 The government took the position of the manufacturer for the purpose of
liability. 114 This legislation was repealed in 1978. 1111 A similar program
of "no-fault" compensation was created by the National Childhood
Vaccine Injury Act. 116 This legislation has a dual purpose. First, it allows easier access to compensation for those children who have suffered
hypersensitivity reactions to vaccines. 117 Second, it provides liability
protection for manufacturers of the vaccine to allow them to continue
their production. 118

C.

Warning

1.

Manufacturer's duty to warn

Products that are both properly designed and correctly manufactured may still be dangerous and will be considered defective if not
accompanied by a proper warning.U 9 The supplier of any product, including the manufacturer of pharmaceuticals, is under a duty to use
reasonable care to warn adequately about the risks associated with the
use of its product. 120 This duty extends to the risks which the manufac111. See, e.g., Collins v. Ortho Pharmaceutical Corp., 195 Cal. App. 3d 1539, 231 Cal.
Rptr. 396 (1986) (The printed opinion is omitted in the California Appellate Reporter).
112. /d. 231 Cal. Rptr. at 404.
113. National Swine Flu Immunization Program of 1976, Pub. L. No. 94-380, 90 Stat.
1113; see also Ducharme v. Merrill-Nat'! Labs., 574 F.2d 1307 (5th Cir.), cert. denied, 439 U.S.
1002 (1978).
114. 90 Stat. 1116.
115. Health and Services Amendments of 1978, Pub. L. 95-626, 92 Stat. 3551.
116. Pub. L. 99-660, 100 Stat. 3755 (codified at 42 U.S.C. §§ 300aa-1 to -33 (1986)).
117. 100 Stat. 3758 (codified at 42 U.S.C. § 300aa-10 (1988)).
118. 100 Stat. 3758-59 (codified at 42 U.S.C. §300aa-11 (1988)).
119. See, e.g., Basko v. Sterling Drug, 416 F.2d 417, 426 (2d Cir. 1969). ("[T]here is no
strict liability . . . unless the consumer first establishes a breach of the manufacturer's duty to
warn . . by showing either (1) that the manufacturer did not warn of a known danger, or (2)
that the manufacturer gave inadequate warnings."); see also Jacobson v. Colorado Fuel & Iron
Corp. 409 F.2d 1263, 1271 (9th Cir. 1969).
120. The Restatement (Second) of Torts defines this knowledge requirement as follows:
(1) The words "reason to know" are used throughout the Restatement . . . to
denote the fact that the actor has information from which a person of reasonable intelligence or of the superior intelligence of the actor would infer that the fact in question
exists, or that such person would govern his conduct upon the assumption that such fact
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turer actually knows of and to those which, through reasonable care, it
should have known. 121
The duty of a pharmaceutical manufacturer to warn arises when
the product is known to cause a particular side effect. The manufacturer is not responsible for unforeseeable or unknown dangers it is unable to discover with reasonable care. 122 Nor is the company a guarantor
of the safety of a product which causes an unusual hypersensitivity reaction if that reaction was not known to be a side-effect of the
product. 123
The "unavoidably dangerous" protection afforded prescription
drugs under Restatement (Second) of Torts § 402A comment k is available, unless the manufacturer has provided an adequate warning of potential adverse reactions. 124 The protection is not available to those
manufacturers who have failed to follow FDA guidelines for testing
and marketing of their product. 1211
Drugs are an exception to the rule requiring a warning of danger
to the ultimate consumer. 128 The drug manufacturer's duty to warn
includes a warning to physicians of the special risks that accompany
normal use. 127 In the majority of cases, there is no duty to warn the
patient directly. 128 For the sake of pharmaceutical warnings, the physician is considered the "learned intermediary" 129 and as such the duty to
exists.
(2) The words "should know" are used throughout the Restatement . . . to denote
the fact that a person of reasonable prudence and intelligence or of the superior intelligence of the actor would ascertain the fact in question in the performance of his duty to
another, or would govern his conduct upon the assumption that such fact exists.
RESTATEMENT (SECOND) OF TORTS§ 12 (1965).
121. See e.g., Lindsay v. Ortho Pharmaceutical Corp., 637 F.2d 87 (2d Cir. 1980); Sterling
Drug, Inc., v. Cornish, 370 F.2d 82 (8th Cir. 1966); lncollingo v. Ewing, 444 Pa. 263, 282 A.2d
206 (1971), rev'd on other grounds, 491 Pa. 561, 421 A.2d 79 (1977)
122. Griggs v. Combe, Inc., 456 So. 2d 790 (Ala. 1984); Freeman v. United States, 704 F.2d
154 (5th Cir. 1983).
123. Gravis v. Parke, Davis & Co., 502 S.W. 2d 863 (Tex. Civ. App. 1973).
124. Davila v. Bodelson, 103 N.M. 243,704 P.2d 1119 (App. 1985).
125. /d.
126. See, e.g., Buckner v. Allergan Pharmaceuticals, 400 So. 2d 820 (Fla. Dist. Ct. App.
1981); Lindsay v. Ortho Pharmaceutical Corp., 637 F.2d 87 (2d Cir. 1980). "[T]he manufacturer's duty is to warn the doctor, not the patient. The doctor acts as an 'informed intermediary'
between the manufacturer and the patient, evaluating the patient's needs, assessing the risks and
benefits of available drugs, prescribing one, and supervising its use." /d. at 91.
127. See, e.g., Fellows v. USV Pharmaceutical Corp., 502 F. Supp. 297 (D. Md. 1980) (The
manufacturer has a duty to provide warnings to physician but the duty does not extend to the
patient); Ezagui v. Dow Chemical Corp., 598 F.2d 727 (2d Cir. 1979).
128. See, e.g., Fellows, 502 F. Supp. at 297.
129. In Reyes v. Wyeth Laboratories, 498 F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096
( 197 4), the court gives an excellent definition of the learned intermediary doctrine.
[W]here prescription drugs are concerned, the manufacturer's duty to warn is limited to
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warn, in most instances, ends when an adequate effort is made by the
company to instruct physicians of the drug's potential side-effects. 130
The pharmaceutical manufacturer has no obligation to warn the ultimate user of dangerous propensities "where there is an intermediary
who is not a mere conduit of the product, but rather administers it on
an individual basis." 131 After the manufacturer gives the physician the
necessary information, it is then the duty of the doctor to warn the
patient. 132 Halcion's warnings are provided to the prescribing physicians. It is their duty, not Upjohn's, to pass the information on to the
patient.
The manufacturer's duty to warn does not end with the purchase
of the drug by the patient. Post-sale warnings are also required. The
manufacturer is considered an expert in regards to its product. 133 As an
expert, the manufacturer has the duty to stay abreast of the scientific
data in the field and the further duty to warn physicians of potential
harm caused by the product. 134
Should an unknown hazard be discovered after the drug has been
sold, the manufacturer is required to make reasonable efforts to inform
the consumer. ~ This requirement is usually satisfied with warnings to
physicians in the form of "Dear Doctor" letters 136 or via detail persons.
One court has said that "[a]lthough a product be reasonably safe when
manufactured . . . risks thereafter revealed by user operation and
brought to the attention of the manufacturer or vendor may impose
upon one or both a duty to warn." 137
13

an obligation to advise the prescribing physician of any potential dangers that may
result from the drug's use . . . . As a medical expert, the prescribing physician can
take into account the propensities of the drug, as well as the benefits of any medication
against its potential dangers . . . . Pharmaceutical companies . . . in selling prescription drugs are required to warn only the prescribing physician, who acts as a "learned
intermediary" between manufacturer and consumer.
ld. at 1276 (5th Cir. 1974).
130. See Leesley v. West, 165 Ill. App. 3d 135, 518 N.E.2d 758 (App. Ct.), appeal denied,
119 Ill. 2d 558, 522 N.E.2d 1246 (1988); Stone v. Smith, Kline & French Laboratories, 447 So.
2d. 1301 (Ala. 1984); Mauldin v. Upjohn Co., 697 F.2d 644 (5th Cir. 1983).
131. Bacardi v. Holzman, 182 N.J. Super. 422, 424, 442 A.2d 617, 618 (1981) (The learned
intermediary doctrine protects a prescription drug manufacturer even where the manufacturer
knew that the physician might not warn the patient).
132. See Crain v. Allison, 443 A.2d 558, 562 (D.C. App. 1982); Salis v. United States, 522
F. Supp. 989, 1000 (M.D. Pa. 1981).
133. Barson v. E.R. Squibb & Sons, 682 P.2d 832 (Utah 1984).
134. !d. at 834 (citing McEwen v. Ortho Pharmaceutical Corp., 270 Or. 375, 528 P.2d 522
(1974)) (actual or constructive knowledge is required).
135. Schenebeck v. Sterling Drug, 423 F.2d 919 (8th Cir. 1970).
136. See Appendix C for an example of a "Dear Doctor" letter.
137. Cover v. Cohen, 61 N.Y.2d 261, 268, 461 N.E.2d 864, 871, 473 N.Y.S.2d 378, 385
(1984) (citations omitted).
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One such drug was Aralan. Initial testing did not show any significant side-effects. However, after use by the general public, evidence of
irreversible blindness in a number of patients was brought to the attention of the manufacturer. The drug manufacturer gave a minimum
amount of credence to this information and chose not to disseminate
these findings to the medical community. The courts repeatedly have
held that the manufacturer was liable because it failed to warn the
public adequately after a side-effect became known. 138
After the Grundberg homicide, the newly discovered side-effects of
Halcion were brought to the attention of Upjohn. Upjohn was required
to warn every licensed physician and pharmacist in the nation of the
previously unknown danger.
The manufacturer is responsible for performing studies of its
product when adverse reactions are reported. The results of these studies, if adverse to the product, must be reported to the public (i.e., doctors).139 This duty to report new adverse findings extends to more than
the research of the manufacturer and includes all industry knowledge
(i.e., state of the art). Constructive knowledge of potential side effects is
presumed with the publication of articles in scientific journals which
relate to the product. 140 A number of these articles concerning Halcion
were published soon after the Grundberg incident. This scientific data
assisted Upjohn in formulating a new adequate warning of its
product. 141
In Lindsay v. Ortho Pharmaceutical Corp., 142 the court explained
that the duty to warn "is a continuous one, requiring the manufacturer
to keep abreast of the current state of knowledge of its product as
gained through research, adverse reaction reports, scientific literature,
and other available methods." 143 Various unsuccessful attempts to legislate a post-sale warning requirement include the proposed Federal
Products Liability Act. 144
138. Sterling Drug v. Yarrow, 408 F.2d 978, 987 (8th Cir. 1969) (manufacturer held liable
for failing to warn of a known side effect); Sterling Drug v. Cornish, 370 F.2d 82, 85 (8th Cir.
1966).
139. See Schenebeck v. Sterling Drug, 423 F.2d 919 (8th Cir. 1970); O'Hare v. Merck &
Co., 381 F.2d 286 (8th Cir. 1967).
140. Feldman v. Lederle Laboratories, 97 N.J. 429, 479 A.2d 374 (1984); see also
Gilhooley, Learned Intermediaries, Prescription Drugs, and Patient Information, 30 ST. Louis
L.J. 633 (1986).
141. See Scrip, supra note 34, at 1.
142. 637 F.2d 87 (2d Cir. 1980).
143. /d. at 92.
144. Product Liability Act, § 44, 99th Cong., 2d Sess. (1984). The following standard was
proposed: "[T]he manufacturer may be responsible for failure to warn if, after the product was
made, the manufacturer discovered or should have discovered the danger which caused the claimant's harm and failed to provide post-manufacture warnings to the claimant as a reasonably pru-
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While the duty of drug manufacturers to provide warnings usually
only extends to the physician, 1411 in cases where the manufacturer
knows that the product will reach the public without individualized
medical intervention, the drug manufacturer must also warn the public
at large. 146 Such an example is immunizations, where everyone is given
a standardized dose of the vaccine without individualized dosing by the
physician. 147 Likewise, birth control pills are given out without much
individual attention. Therefore, no protection exists for the drug producer under the learned intermediary rule in situations where the manufacturer had actual or constructive knowledge of the potential for the
public to acquire the product without significant physician intervention. 148 Halcion does not fall into this category because direct physician
contact is required before a patient has access to the drug.

2.

Adequacy of warning

Adequacy of the warning is a major issue in determining reasonableness. If the warning is adequate, then the defendant drug producer
will usually prevail, even if the product is unavoidably unsafe. 149 Adequacy of the warning is achieved when it is obviously displayed, when
it gives a fair appraisal of the extent of the danger, and when it properly instructs the user in how to use the product. 1110 Likewise, a warning is adequate when it "warns with the degree of intensity demanded
by the nature of the risk." 1111 A warning, however, may be inadequate
if it is "unduly delayed, reluctant in tone or lacking in a sense of urdent person would have done." /d.
145. See Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981); Dyer v. Best
Pharmacal, 118 Ariz. 465, 577 P.2d 1084 (Ct. App. 1978).
146. This is the standard in vaccines and mass immunizations. See Reyes v. Wyeth Laboratories, 498 F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096 (1974); Davis v. Wyeth Laboratories, 399 F.2d 121 (9th Cir. 1968).
147. Brazzell v. United States, 788 F.2d 1352 (8th Cir. 1986).
148. Williams v. Lederle Laboratories, 591 F. Supp. 381 (S.D. Ohio 1984).
149. Formella v. Ciba-Geigy Corp., 100 Mich. App. 649, 300 N.W.2d 356 (1980).
150. Madden, The Duty to Warn in Products Liability: Contours and Criticism, 89 W. VA.
L. REv. 221, 310-20 (1987); Richards v. Upjohn Co., 95 N.M. 675,679,625 P.2d 1192, 1196
(Ct. App. 1980). To be considered adequate:
1. the warning must adequately indicate the scope of the danger;
2. the warning must reasonably communicate the extent or seriousness of the harm that
could result from misuse of the drug;
3. the physical aspects of the warning must be adequate to alert a reasonably prudent
person to the danger;
4. a simple directive warning may be inadequate when it fails to indicate the consequences that might result from failing to follow it; and .
5. the means to convey the warning must be adequate.
/d.
151. Seley v. G.D. Searle & Co., 67 Ohio St. 2d 192, 198, 423 N.E.2d 831, 837 (1981).
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gency." 162 Prior to Grundberg, Halcion's package insert warned of the
potential for serious side effects including in "[ r]are (i.e., less than
0.5%) [cases] death from hepatic failure." 153 Whether or not this type
of warning was adequate is a question for the jury to decide.
Even if an adequate warning is given of the risk, it will not insulate the manufacturer from liability when a cure for the defect could
have been accomplished with little effort. The court in Brochu v. Ortho
Pharmaceutical Corp. found that "when an unreasonable danger could
have been eliminated without excessive cost or loss of product efficiency, liability may attach even though . . . there was adequate warning."164 Moreover, the value of an adequate warning may be diminished by statements which lead the user to minimize the importance of
the warning. For example, a warning of one manufacturer concerning
birth control pills contained studies showing an increased incidence of
thrombosis in British women. The court held that having a study dealing with British women did little to amplify concern of thrombosis in
American women and therefore did not adequately warn this group. 166
In addition, most courts require warnings to be given if an allergic
reaction may affect a substantial number of people. 156 Some courts have
required a duty to warn of rare adverse reactions if the end result
would be exceedingly serious. 167 The Restatement (Second) of Torts
states that "[ w ]here . . . the product contains an ingredient to which a
substantial number of the population are allergic . . . the seller is required to give warning . . . and a product bearing such a warning,
which is safe for use if it is followed, is not in defective condition, nor is
it unreasonably dangerous." 158

3.

Methods of warning

Warnings may be satisfied in a number of ways. Labeling, package inserts, advertising, and interaction with drug company detail persons may all act as adequate warnings to decrease liability.
a. Labeling. The FDA has numerous requirements for the label152. /d.
153. See the copy of the package insert found within Appendix A.
154. 642 F.2d 652, 655 (1st Cir. 1981) (quoting Thibault v. Sears, Roebuck & Co., 118
N.H. 802, 808, 395 A.2d 843, 847 (1978)).
155. McEwen v. Ortho Pharmaceutical Corp., 570 Or. 375, 528 P.2d 522 (1974).
156. Kaempfe v. Lehn & Fink Prods. Corp., 21 A.D.2d 197, 249 N.Y.S.2d 840 (App. Div.
1964), affd, 20 N.Y.2d 818, 231 N.E.2d 294, 284 N.Y.S.2d 818 (1967).
157. Tomer v. American Home Prod. Corp., 170 Conn. 681, 368 A.2d 35 (1976); Crocker v.
Winthrop Laboratories, 514 S.W.2d 429 (Tex. 1974) (Drug manufacturers must properly warn
of rare adverse reactions if they may be severe).
158. RESTATEMENT (SECOND) OF ToRTS§ 402A (1965).
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ing of pharmaceuticals. 1119 These are minimum requirements only and
do not relieve the manufacturer of its duty to fully warn of dangers for
which it has actual or constructive knowledge. 180 The basic labeling
regulation as promulgated by the FDA is that all material facts relating
to the drug are to be presented on the package. 181
An FDA special advisory committee on September 22, 1989,
unanimously recommended the agency change Halcion's label to advise
doctors that the drug may be more likely to cause amnesia than similar
medications. 182 The committee further recommended that the FDA revise the labels of all hypnotic benzodiazepines. 183 Their major concern
was to warn of "traveler's amnesia," a condition that occasionally occurs when a person takes a long-acting sleeping pill to sleep a relatively
short period of time. 184
b. Package inserts. The package insert is the method developed by
the FDA for instructing physicians and patients about the make-up,
side-effects, indications, and dosing of the product. 1811 The most important feature of the package insert is the requirement that the information contained therein is completely based on substantial evidence. No
"hype" or promotion is permitted to be included. Because physicians
have almost unlimited access to drug information through a variety of
sources, the package insert is not intended to be the most current repository of information concerning the benefits of a drug. Instead, it has
the purpose of informing the physician of any substantial evidence that
has been found relating to the drug's benefits or side-effects. 188
159. 21 C.F.R. § 201 (1990).
160. Feldman v. Lederle Laboratories, 97 N.J. 429, 479 A.2d 374 (1984).
161. 21 C.F.R. § 201.5-.10 (1990) ("Labeling of a . . . drug . . . shall be deemed to be
misleading if it fails to reveal facts that are . . . material.").
162. Sleeping Pill Not Serious Health Threat, United Press Int'l, Sept. 23, 1989 (LEXIS,
Nexis, Omni file).
163. Benzodiazepines are replacing barbiturates as the most prescribed sedatives. Various
benzodiazepines show a great difference in their side-effect profile. The major side-effects within
this family of drugs include drowsiness, fatigue, and ataxia. More significant but less common
side-effects include: Rage, hostility, paranoia, hallucinations, depression, insomnia, nightmares,
and anterograde amnesia. Drugs That Cause Psychiatric Symptoms, 31 MEDICAL LETTER 114
(1989).
164. See Sleeping Pill Not Serious Health Threat, supra note 162.
165. Pharmaceutical Mfr. Ass'n v. Food & Drug Admin., 484 F. Supp. 1179 (D. Del.
1980).
166. The court in Pharmaceutical Manufacturers Ass'n stated that
Congress intended patients using prescription drugs, as well as those using over-thecounter drugs, to receive 'facts material with respect to consequences which may result
from the use . . .' When it is determined that the possible side effects of a drug when
used as customarily prescribed are sufficiently serious as to be material to the patient's
decision on use of the drug, [the FDA] may require disclosure of those side effects on
the labeling.
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The package insert contains information based on data submitted
to the FDA by the manufacturer dealing with the safety and efficacy of
the drug. 187 A physician is not required to follow the instructions of the
package insert. If the doctor chooses not to do so, he or she may be
concerned about increased liability. 188 This fear leads many physicians
to practice cookbook medicine (i.e., following the product insert instructions implicitly without regard to the patient's individual reactions).
However, in general, most physicians are not the dispenser of drugs
and so they do not see the product inserts, which can be problematic.
Likewise, while pharmacists have access to inserts, they usually rely on
computer data for the majority of their product information.
Some courts construe a manufacturer's failure to comply with
rules requiring package inserts as constituting negligence per se. 189
Other courts have held that failure to follow statutory regulation concerning inserts is not a controlling issue. 170 Within Halcion's package
insert, Upjohn has always included the information required by the
FDA. The most recent change occurred after the Grundberg incident.
At that time, Upjohn discontinued the 0.5 mg dosage and added a
warning of "traveler's amnesia" and "anterograde amnesia" to Halcion's package insert. 171
c. Advertising. Emphasis on product promotion is one of the more
controversial actions of the pharmaceutical industry. Manufacturers
spend over one-fourth of gross income from drug sales on marketing. 172
The majority of this money is spent on advertising and detail persons.
The Pharmaceutical Manufacturers Association, realizing the importance of this issue, has promulgated the Code of Fair Practices in the
Promotion of Drug Products. 178 But, as with many such professional
ethical codes, the written word is often overlooked for an improved bottom line.
Drug manufacturers are the dominant, if not the only, source of
information about drug risks and benefits for most prescribing physicians. Other independent sources of information, such as medical jourld. at 1186.
167. 21 C.F.R. § 201.5 (1990).
168. Ohligschlager v. Proctor Community Hosp., 55 Ill. 2d 411, 303 N.E.2d 392 (1973)
(The court held that the physician's deviation from the package insert constituted negligence.).
169. Lukaszewicz v. Ortho Pharmaceutical Corp., 510 F. Supp. 961, amended, 532 F. Supp.
211 (E.D. Wis. 1981).
170. See MacDonald v. Ortho Pharmaceutical Corp., 394 Mass. 131,475 N.E.2d 65 (1985),
cert. denied, 474 U.S. 920 (1985).
171. See Scrip, supra note 34, at I.
172. Harrell, Pharmaceutical Marketing, in THE PHARMACEUTICAL INDUSTRY 80 (C.
Lindsay ed. 1978).
173. See Appendix D.
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nals, may be reluctant to publish research criticizing products of drug
manufacturers because drug advertising makes up the largest share of
medical journal revenue. 174
Courts have held drug manufacturers liable for advertisements
which dilute proper warnings or reduce reliance of the physician on a
package insert. 1711 For example, Parke-Davis, the manufacturer of
chloramphenicol, provided warnings in its package insert on the dangers of aplastic anemia with use of the drug. The California Supreme
Court found that Parke-Davis had diluted the effect of the warning to
such a degree, through advertising and promotional schemes, that it
caused doctors to disregard the package insert. 176 Courts have held that
a company incurs liability if it causes a prescribing physician to disregard the warnings that are mandated by the FDA. 177 Some courts have
held the manufacturer liable, even when the physician acted in a negligent manner, if the physician's actions were induced through overpromotion.178
Drug manufacturers may be held to a warranty standard based on
advertising. 179 Drug manufacturers rarely expose themselves to liability
by expressly warranting their products. 180 Instead, exposure to breach
of warranty liability most often arises through implied warranty and
misrepresentation. 181 In its advertisements, Upjohn has always asserted
174. SeeS. GREENBERG, THE QUALITY OF MERCY 267-83 (1971).
175. Love v. Wolf, 226 Cal. App. 2d 378, 38 Cal. Rptr. 183 (1964). The court stated:
[I]f such over-prescription by the doctor was not caused by the over-promotion of
Parke-Davis, then, however negligent such over-promotion may have been, Parke-Davis could not be held liable. Its negligence would not have been an inducing, or proximate, cause of the resulting injuries. Dr. Wolfs negligence would have been an intervening, independent, and solely proximate cause . . . .
On the other hand, if the over-promotion can reasonably be said to have induced
the doctor to disregard the warnings previously given, the warning given is thereby
withdrawn or cancelled, and if, furthermore, the jury could have found that the doctor
here actually prescribed the drug to cure an infection for which the company's advertising or its detail men could actually have recommended its use, then the pharmaceutical
company's negligence remains as an inducing cause coinciding with the negligence of
the doctor to produce the result.
Wolf, 226 Cal. App. at 399-400, 38 Cal. Rptr. at 196 (citation omitted).
176. /d.
177. See Toole v. Richardson- Merrell, Inc., 251 Cal. App. 2d 689, 60 Cal. Rptr. 398 (1967).
178. See, e.g., Stevens v. Parke, Davis & Co., 9 Cal. 3d. 51, 507 P.2d 653, 107 Cal. Rptr. 45
(1973).
179. /d.
180. But see Spiegel v. Saks 34th Street, 43 Misc. 2d 1065, 252 N.Y.S.2d 852 (Sup. Ct.
1964), affd, 26 A.D.2d 660, 272 N.Y.S. 972 (1966) (A product advertised as absolutely safe is
subject to litigation for breach of express warranty).
181. An implied warranty may be breached when a manufacturer fails to warn adequately of
known dangers. See supra notes 115-116 and accompanying text.
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Halcion's rapidity of action, fast elimination, and daytime alertness. 182
Since the Grundberg incident, Upjohn has emphasized the safety of the
product. 183
d. Detail persons. Detail persons, the sales representatives of ethical drugs, occupy a position different than that of other sales persons.
Their potential misrepresentation of the product, rather than being
harmless fluff, may lead to death or disfigurement of the ultimate consumer. Detail persons, acting as liaison between physicians and manufacturer, are the most common transmitters of new information concerning pharmaceuticals. The pharmaceutical industry employs almost
40,000 detail persons. 184
Detail persons are frequently torn between a desire to increase the
substantial profits of the drug manufacturer 1811 and a duty to inform the
physician of product side-effects and possible contra-indications. Great
potential exists for detail persons to mislead physicians in order to increase sales. Manufacturers are vicariously liable for the actions of the
detail persons which are within the scope of their employment. 186 Some
courts have held that the liability extends even beyond the scope of
employment. 187
An otherwise adequate warning provided by the company can be
nullified by an overzealous detail person. High pressure sales by intense, occasionally knowledgeable, detail persons often determine physician-use patterns. Even though the oral communications of detail persons are difficult to monitor as to completeness or accuracy, drug
companies cannot escape liability for improper over-promotion of safety
by detail persons. 188
If the detail person convinces the doctor to disregard warnings
provided by the manufacturer, the company may be held liable as the
cause of the injury. 189 At least one court has held that detail persons
182. For examples of Halcion advertisements, see Prager, supra note 42.
183. Jd.
184. PHARMACEUTICAL MANUFACTURERS ASSOCIATION, PRESCRIPTION DRUG INDUSTRY
FACT BooK 56 (1986).
185. See generally j. LIDSTONE, MARKETING PLANNING FOR THE PHARMACEUTICAl. INDUSTRY (1987); R. NORRIS, PII.I.S PESTICIDES AND PROFITS (1982).
186. RESTATEMENT (SECOND) OF AGENCY § 229 (1958).
187. See, e.g., Schering Corp. v. Cotlow, 94 Ariz. 365, 385 P.2d 234 (1963).
188. Most physicians tolerate visits and direct sale attempts by detail persons in order to
acquire samples of medications. Detail persons frequently use tactics of peer pressure ("all the
doctors in this area are using my drug"), bribery ("if you do a study on 200 of your patients using
my drug, then the company will award you an honorarium of a trip to Europe to continue your
research"), and humiliation ("chiropractors are the only people still suggesting using the other
medication") to push their product. Survey of doctors at MacDonald Health Center, Brigham
Young University, March 1990 (on file at the BYU Journal of Public Law office).
189. Stevens v. Parke-Davis- & Co., 9 Cal. 3d. 51, 107 Cal. Rptr. 45, 507 P.2d 653 (1973)
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have a duty to warn of potential adverse reactions. 190 Liability is possible because the doctor might otherwise have been aware of the risks
that were involved had the detail persons given adequate warning. 191

D.

Causation

As in negligence actions, causation must be proved in strict tort
liability. Professor Prosser states that "[ s]trict liability eliminates both
privity and negligence; but it still does not prove the plaintiffs case." 192
The standard elements of proof, as enumerated in § 402A of the Restatement (Second) of Torts, are: first, proof that the product was defective; second, proof that the defect existed at the time it left the control of the defendant; third, proof that the defect created a product that
was unreasonably dangerous for the intended or foreseeable use; and,
fourth, proof that the defect caused the injury. 193 Within the pharmaceutical industry, the most common ways to prove causation are epidemiological and statistical studies, expert testimony, direct or circumstantial evidence, or a combination of these methods. 194
In situations where the plaintiff is unable to identify the defective
product's specific manufacturer, an industry-wide liability has been devised.1911 Liability may be imposed on every manufacturer of a generic
product. It is then the responsibility of the various defendants to prove
they did not supply the defective product. 196 Industry-wide liability,
(An active sales program, led by a detail person, convinced a doctor to disregard the package insert
warnings); Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d. 689, 709, 60 Cal. Rptr. 398,
413-14 (1967) (Company did not warn of known adverse reactions).
190. Incollingo v. Ewing, 444 Pa. 263, 289, 282 A.2d 206, 220 (1971), rev'd on other
grounds, 491 Pa. 561, 421 A.2d 1027 (1977):
We think that whether or not the warnings on the cartons, labels and literature of
Parke, Davis in use in the relevant years were adequate, and whether or not the
printed words of warning were in effect cancelled out and rendered meaningless in the
light of the sales effort made by the detail men, were questions properly for the jury.
Action designed to stimulate the use of a potentially dangerous product must be considered in testing the adequacy of a warning as to when and how the product should not
be used; if detail men are an effective means of selling a product and explaining its
nature, a jury could find that they also afforded an effective medium of conveying a
warning.
191. See, e.g., Schenebeck v. Sterling Drug, 423 F.2d 919 (8th Cir. 1970); Krug v. Sterling
Drug, Inc., 416 S.W.2d 143 (Mo. 1967).
192. Prosser, The Fall of the Citadel (Strict Liability to the Consumer), 50 MINN. L. REv.
791, 840 (1966).
193. RESTATEMENT (SECOND) OF ToRTS § 402A (1965).
194. Middlekauff, The Current Law Regarding Toxic Torts: Implications for the Food Industry, 41 FooD DRUG CosM. L.J. 387, 404-05 (1986).
195. Comment, Industry Wide Liability, 13 SuFFOLK U.L. REV. 980 (1979); Mulcahy v. Eli
Lilly & Co., 386 N.W.2d 67 (Iowa 1986) (DES market share liability).
196. Comment, The Market Share Theory: Sindell's Contribution to Industry Wide Liability, 19 Hou. L. REv. 107 (1982).
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however, is not an issue in Grund berg since U pjohn 1s the sole producer of Halcion.
Since the product is destroyed by ingestion at the time of injury, it
is difficult to prove a drug was manufactured defectively. This difficulty is amplified because the plaintiff must prove that the drug was
defective at the time it left the control of the manufacturer and that the
defect was present at the time of injury .197 On the other hand, a design
defect is easier to prove because all of the same type of drugs are
equally defective and available for testing. In a failure to warn case, the
plaintiff must prove that lack of proper warning was the proximate
cause of the injury. The failure to warn must be the direct link between
the product and the injury. The plaintiff must further show the manufacturer either knew or should have known the danger of harm from
the drug. 198
Defendant liability may be severed by the introduction of an intervening cause. In strict liability litigation, courts appear very willing to
view intervening causes as being unforeseeable. 199
Most courts view the terms "user" and "consumer" liberally. Historically, privity was required before permitting recovery. Today, a
user may be far removed from the initial privity of contract. 200 If it is
foreseeable that a person will be a user, then that person is a potential
plaintiff. 201
It is not necessary to prove that Halcion was the only cause of the
injury, only that it was one of the causes. If, for example, the patient
were to ingest multiple drugs, then each drug might be viewed as a
cause-in-fact of the subsequent harm. At least one court has held a
manufacturer of one defective drug liable for the entire injury sustained
by the ingestion of multiple drugs. 202
The foreseeability of the harm caused by a product is an issue in
many courts. 208 If it is not foreseeable that Mrs. Grund berg would
shoot her mother, then this is not the type of injury that would induce
liability. Some courts now reject the foreseeability of the harm ap197. RESTATEMENT (SECOND) OF TORTS§ 402A.
198. /d.
199. See generally D. FISCHER & W. PowERS JR., supra note 89, at 409-11.
200. RESTATEMENT (SECOND) OF ToRTS § 402A comment I (1965). Comment I provides:
He may be a member of the family of the final purchaser, or his employee, or a guest
at his table, or a mere donee from the purchaser. The liability stated is one in tort, and
does not require any contractual relation, or privity of contract, between the plaintiff
and the defendant.
201. Winnett v. Winnett, 57 Ill. 2d 7, 310 N.E.2d I (1974).
202. Basko v. Sterling Drug, 416 F.2d 417 (2d Cir. 1969).
203. Helene Curtis Indus. v. Pruitt, 385 F.2d 841, 859-64 (5th Cir. 1967); Bigbee v. Pacific
Tel. & Tel. Co., 34 Cal. 3d 49, 665 P.2d 947, 192 Cal. Rptr. 857 (1983).
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proach and instead look to the foreseeability of the use. 204
E.

Physician and I or Pharmacist Liability

It is unfortunate that many physicians and pharmacists are ignorant of the potential side-effects associated with the drugs they prescribe. One study revealed that under thirteen percent of drug use was
evaluated as rational, twenty-one-and-one-half percent was considered
questionable, and amazingly over sixty-five percent was judged irrational. 2011 Because of the prevalence of drugs in the treatment of patients, it is conceivable that every malpractice case could have a pharmaceutical component.
The application of traditional liability rules to pharmaceutical
manufacturers is problematic. For example, the defined consumer of
prescription drugs is the physician, not the patient. The patient has
little input into the drug selected by the physicians. The physician
holds a position as a "learned intermediary" and as such takes upon
himself some of the manufacturer's liability even in the case of product
defect. 206 The physician who prescribed Halcion to Mrs. Grundberg
could be liable for all side-effects he or she should have known if he
failed to warn the patient adequately.
Physicians and pharmacists who find themselves in a suit resulting
from a defective product have some recourse. 207 There is a potential
tort action against the manufacturers of the defective products for both
the injury to the patient and for damage to reputation and earnings. 208
In many circumstances, this leads to plaintiffs playing one potential
defendant against another. 209

204. See e.g., Baker v. International Harvester Co., 660 S.W.2d 21 (Mo. Ct. App. 1983).
205. M. SILVERMAN & P. LEE, supra note 103, at 289-90.
206. Comment, Strict Tort Liability/ Negligence/ Prescription Drugs: A Pharmaceutical
Company Owes No Duty to a Non-Patient Third Party to Warn Doctors or Hospitals of the Side
Effects of a Drug and a Hospital or Doctor Owes No Duty to a Non-Patient Third Party to
Warn a Patient of the Effects of a Prescription Drug, 77 ILL B.J. 227 (1988); Comment,
Torts-Duty to Warn-Incorrect Prescription of Unavoidably Unsafe Drugs, 22 KAN. L. REv.
281 (1984).
207. See Merrill, Compensation for Prescription Drug Injuries, 59 VA. L. REV. 1, 50-68
(1973).
208. See, e.g., Oksenholt v. Lederle Laboratories, 294 Or. 213, 656 P.2d 293 (1982);
Mobilia, Allergic Reactions to Prescription Drugs: A Proposal for Compensation, 48 ALB. L.
REV. 343, 364-65 (1984).
209. See Willig, Physicians, Pharmacists, Pharmaceutical Manufacturers: Partners in Patient Care, Partners in Litigation~, 37 MERCER L. REv. 755 (1986).
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Defenses

Defenses to strict products liability differ from one jurisdiction to
the next. In Utah, Upjohn has three potential defenses: assumption of
the risk, comparative fault, and misuse.

1.

Assumption of the risk

The Restatement (Second) of Torts describes assumption of the
risk as "the form of contributory negligence which consists of voluntary
and unreasonable encounter of a known danger." 210 If the consumer
knew of the product's defect but disregarded the danger and used the
product, he or she is barred from seeking to recover against the defendant. The defendant must prove that the plaintiff knew and understood
the danger and that the plaintiff "voluntarily and unreasonably" consented to being exposed to it. 211
Assumption of the risk is an essential concept for pharmaceutical
litigation defense. If adequate warning is given to the doctor arid the
doctor disregards these dangers, then the physician/patient has assumed some of the risk for potential adverse reactions. Since creating
Halcion, Upjohn has maintained a warning against certain uses of its
product. One such warning suggested discontinuing use of the drug after one month and warned of the chance for increased side-effects with
long term use. By prescribing the drug over a longer period of time, the
physician/patient may have assumed the risk of increased side-effects.

2.

Comparative fault

Comparative fault measures the plaintiffs fault in comparison to
the manufacturer's fault and places upon each a percentage value.
Most states that have comparative negligence systems have applied a
comparative fault scheme to strict tort liability litigation. 212 For negligence actions in Utah, a statutory "49 /51" comparative fault system
exists. 213 In this system, if the plaintiff is more than half at fault, no
recovery is permitted. This is not the case in strict tort liability where a
"pure" comparative fault system exists. 214 In a pure system, a plaintiff
may recover the percent of damage caused by the defendant, regardless
of the fault attributable to the plaintiff. 216
210.
211.
212.
(1978).
213.
214.
215.

RESTATEMENT (SECOND) OF TORTS § 402A comment n (1965).
Smith v. Clayton & Lambert Mfg. Co., 488 F.2d 1345, 1349 (10th Cir. 1973).
Daly v. General Motors Corp., 20 Cal. 3d 725, 575 P.2d 1162, 144 Cal. Rptr. 380
Mulherin v. Ingersoll-Rand Co., 628 P.2d 1301, 1303-04 (Utah 1981).

ld.
/d.
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The goal of strict tort liability is not to create in the manufacturer
an insurer for product-induced injuries. Comparative fault provides
more equity in allocating risks and preventing manufacturers and other
consumers from sharing in the costs attributable to those who fail to use
products carefully. Most courts which have permitted a comparative
fault defense have also permitted defenses of assumption of the risk and
misuse. 218 The jury is usually instructed to combine the percentage
from each of these defenses and give the percentage of fault as the sum
of the three. 217
If Halcion were shown to have a particular defect, Mrs.
Grundberg would be able to recover for the percentage of damage induced by the defect. The total damage would be calculated, and the
percentage of fault she caused would be deducted from the award.

3.

Product misuse

The defense of product misuse is permitted when the plaintiff has
used a product for a purpose not reasonably foreseeable to the manufacturer.218 The Restatement (Second) of Torts recognizes the defense
of product misuse. Comment h of § 402A provides: "If the injury results from abnormal handling . . . the seller is not liable." 219 The defense of misuse may be utilized if the plaintiff's misuse of the product
was a contributing cause of the injury. 220
To use this defense, the plaintiff's misuse of the product must be
unforeseeable. 221 The definition of unforeseeable is the important issue.
Taking four times the standard dosage of a medication may be foreseeable, but five times may be unforeseeable. There is no standard, fixed,
arbitrary cutoff. It is left for the fact finder to determine foreseeability
on a case-by-case basis.
216. See generally Fischer, Products Liability-Applicability of Comparative Negligence to
Misuse and Assumption of the Risk, 43 Mo. L. REv. 643 (1978).
217. See, e.g., Duncan v. Cessna Aircraft Co., 665 S.W.2d 414 (Tex. 1984).
218. Perfection Paint & Color Co. v. Konduris, 147 Ind. App. 106, 107, 258 N.E.2d 681,
682 (1970).
219. RESTATEMENT (SECOND) OF TORTS § 402A comment h (1965). Comment h provides:
A product is not in a defective condition when it is safe for normal handling and
consumption. If the injury results from abnormal handling, as where a bottled beverage
is knocked against a radiator to remove the cap, or from abnormal preparation for use,
as where too much salt is added to food, or from abnormal consumption, as where a
child eats too much candy and is made ill, the seller is not liable. Where, however, he
has reason to anticipate that danger may result from a particular use, as where a drug
is sold which is safe only in limited doses, he may be required to give adequate warning
of the danger (see Comment j), and a product sold without such warning is in a defective condition.
220. Mulherin v. Ingersoll-Rand Co., 628 P.2d 1301, 1302 (Utah 1981).
221. /d.
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Upjohn claims that Mrs. Grundberg misused Halcion by taking it
longer than was suggested in the product insert and in higher doses
than was intended by the manufacturer. 222 If Upjohn can prove these
allegations to the jury, then the defense of misuse will restrict her
recovery.

G.

Damages

Similar to negligence litigation, strict liability provides for property and personal damage recovery. 223 With both negligence and strict
liability, damage is part of a prima facia case. 224 Mrs. Grundberg and
her mother's estate seek six million dollars in general damages and fifteen million dollars in punitive damages. 2211
Commentators have differed in their views of punitive damage
awards in strict liability litigation. Some assert that punitive damage
awards should be granted as punishment for wanton, willful, reckless,
malicious, or "outrageous conduct." 226 Other jurisdictions grant punitive damage awards as a form of deterrence to others who might commit the same outrageous conduct. 227 Most jurisdictions use punitive
damages for any combination of the above reasons. 228
Punitive damage awards are common in strict liability litigation
involving pharmaceutical products. 229 The plaintiff has the burden of
proving the defendant's outrageous conduct by "clear and convincing
proof." 230 Punitive damage awards serve to punish inappropriate manufacturing practices and to stop "product suppliers from making eco222. This information is contained in a letter from Lawrence C. Hoff, President and Chief
Operating Officer of Upjohn to John Sias, President of ABC, Inc. The letter was sent in response
to the "20/20" broadcast of Feb. 17, 1989, which dealt with the Grundberg incident. A copy of
the letter is found in Appendix B.
223. See RESTATEMENT (SECOND) OF TORTS § 402A (1965).
224. A prima facie case of negligence requires a duty owed by the defendant to the plaintiff,
breach of that duty, causation, and damages. See generally W. PRoSSER, LAw OF ToRTS § 96
(4th ed. 1971).
225. See Prager, supra note 42.
226. See RESTATEMENT (SECOND) OF TORTS § 908(2) (1965). Section 908(2) provides:
Punitive damages may be awarded for conduct that is outrageous, because of the
defendant's evil motive or his reckless indifference to the rights of others. In assessing
punitive damages, the trier of fact can properly consider the character of the defendant's act, the nature and extent of the harm to the plaintiff that the defendant caused or
intended to cause and the wealth of the defendant.
227. See, e.g., Malcolm v. Little, 295 A.2d 711 (Del. 1972).
228. See, e.g., Miller v. Watkins, 200 Mont. 455, 653 P.2d 126 (1982); Newton v. Standard
Fire Ins. Co., 291 N.C. 105, 229 S.E.2d 297 (1976); see also W. KEETON, D. DoBBS, R. KEETON
& D. OWEN, PROSSER AND KEETON ON TORTS, § 2, at 9 (5th ed. 1984).
229. See Hoffman v. Sterling Drug, 485 F.2d 132, 144-47 (3d Cir. 1973).
230. Acosta v. Honda Motor Co., 717 F.2d 828, 833 (3d Cir. 1983).
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nomic decisions, not to remedy the defects of the product." 231 The most
common type of drug cases in which punitive damages are granted are
where the manufacturer had knowledge of adverse reactions but failed
to properly warn of the danger. 232
V.

CONCLUSION

The public should be free to purchase goods without fear of defect.
Strict tort liability is a valid means to insure that products function
without injury. On the other hand, it is unreasonable for all products to
be totally safe and risk free for consumers. A knife with a dull blade
might be safer than with a sharp blade, but part of the sharp knife's
efficacy is due to the very cause of its dangerous propensity, namely its
sharpened edge. Ice cream would be safer without the heavy cholesterol
content but the joy in eating it comes from its richness which clogs our
arteries. Medication is unique because it is ingested into the body with
the knowledge that in a certain number of individuals there will be
serious side-effects. This is just as true for over-the-counter medications, such as aspirin or Tylenol, as it is for prescription-strength medication, such as Halcion.
It is true that drugs can be made safer, but, even so, certain idiosyncratic reactions will occur which will cause a few to suffer. The
answer for those few individuals might be for the government or the
manufacturer to set up a trust fund for such reactions which could be
drawn upon when a severe reaction occurs. Rather than hamper the
medical establishment with increased liability, the courts should take
the forefront in the fight to provide a strong defense for drug
manufacturers.
Prior to Grundberg, Upjohn gave a proper warning for the potential dangers of Halcion. The majority of possible adverse reactions to
Halcion were discussed in that warning. Unless it can be shown that
Upjohn was not diligent in testing the drug, the manufacturer should
not be held responsible for an unknown reaction, no matter how serious
the consequences.

231. Neal v. Carey Canadian Mines, 548 F. Supp. 357 (E.D. Pa. 1982), affd, Van Buskirk
v. Carey Canadian Mines, 791 F.2d 30 (3rd Cir. 1986).
232. See G.D. Searle & Co. v. Superior Court, 49 Cal. App. 3d 22, 122 Cal Rptr. 218
(1975); Roginsky v. Richardson-Merrell, Inc., 378 F.2d 832 (2d Cir. 1967); Toole v. RichardsonMerrell, Inc., 251 Cal. App. 2d 689, 60 Cal. Rptr. 398 (1967).

102

B.Y.U. JOURNAL OF PUBLIC LAW

[Volume 5

APPENDIX A
DESCRIPTION
HALCION Tablets contain triazolam, a triazokobenzodiazepine hypnotic agent.
Triazolam is a white crystalline powder, soluble in alcohol and poorly soluble in water. It
has a molecular weight of 343.21.
The chemical name for triazolam is 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-u][ 1.4] benzodiazepine.
The structural formula is represented below:

Cl

Each HALCION tablet, for oral administration, contains 0.125 mg. or 0.25 mg. of triazolam.
Inactive ingredients 0.125 mg-cellulose, corn starch, docusate sodium, FD&C red no. 3, FD&C
blue no 2 lactose magnesium stearate sodium benzoate. 0.25 mg-cellulose, corn starch, docusate
sodium, FD&C blue no 2, lactose, magnesium stearate, silicon dioxide, sodium benzoate.
CLINICAL PHARMACOLOGY
Triazolam is a hypnotic with a short mean plasma half-life reported to be in the range of 1.5
to 5.5 hours. In normal subjects treated for seven days with four times the recommended dose,
there was no evidence of altered systemic bioavailability, rate of elimination, or accumulation.
Peak plasma levels are reached within 2 hours following oral administration. Following recommended doses of HALCION, triazolam peak plasma levels in the range of I to 6 ng/ml are seen.
The plasma levels achieved are proportional to the dose given.
Triazolam and its metabolites, principally as conjugated glucuronides which are presumably
inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam
appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion. Urinary excretion appeared to be biphasic in its time course.
HALCION Tablets 0.5 mg. in two separate studies, did not affect the prothrombin times or
plasma warfarin levels in male volunteers administered sodium warfarin orally.
Extremely high concentrations of triazolam do not displace bilirubin bound to human serum
albumin in vitro.
Triazolam 14 C was administered orally to pregnant mice. Drug-related material appeared
uniformly distributed in the fetus with 14 C concentrations approximately the same as in the brain
of the mother.
In sleep laboratory studies, HALCION Tablets significantly decreased sleep latency, increased the duration of sleep and decreased the number of nocturnal awakenings. After two weeks
of consecutive nightly administration, the drug's effect on total wake time is decreased, and the
values recorded in the last third of the night approach baseline levels. On the first and/or second
night after drug discontinuance (first or second post-drug night), total time alseep, percentage of
time spent sleeping, and rapidity of falling asleep frequently were significantly less than on baseline (pre-drug) nights. This effect is often called "rebound" insomnia.
The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine drugs may be influenced by the biologic half-life of administered drug
and any active metabolites formed. When half-lives are long, drug or metabolites may accumulate
during periods of nightly administration and be associated with impairments of cognitive and mo-
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tor performance during waking hours, the possibility of interaction with other psychoactive drugs
or alcohol will be enhanced. In contrast, if half-lives are short, drug and metabolites will be
cleared before the next does is ingested, and carry-over effects related to excessive sedation or CNS
depression should be minimal or absent. However, during nightly use for an extended period,
pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop. If the drug has a short half-life of elimination, it is possible that a relative deficiency of the
drug or its active metabolites (ie, in relationship to the receptor site) may occur at some point in
the interval between each night's use. This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine
hyponotics: 1) increased wakefulness during the last third of the night, and 2) the appearance of
increased signs of day-time anxiety reported by one author in a selected group of patients.
INDICATIONS AND USAGE
HALCION Tablets contain triazolam which is a hypnotic agent useful in the short-term
managment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
In polysomnographic studies in man of 1 to 42 days duration, triazolam decreased sleep latency, increased duration of sleep, and decreased the number of nocturnal awakenings.
It is recommended that HALCION not be prescribed in quantities exceeding a one-month
supply.
CONTRAINDICATIONS
HALCION Tablets are contraindicated in patients with known hypersensitivity to this drug
or other benzodiazepines.
Benzodiazepines may cause fetal damage when administered during pregnancy. An increased
risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during
the first trimester of pregnancy has been suggested in several studies. Transplacental distribution
has resulted in neonatal CNS depression following the ingestion of therapeutic doses of a
benzodiazepine hypnotic during the last weeks of pregnancy.
HALCION is contraindicated in pregnant women. If there is a likelihood of the patient
becoming pregnant while receiving HALCION she should be warned of the potential risk to the
fetus. Patients should be instructed to discontinue the drug prior to becoming pregnant. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy
should be considered.
WARNINGS
Overdosage may occur at four times the maximum recommended therapeutic dose (See DOSAGE & ADMINISTRATION). Patients should be cautioned not to exceed prescribed dosage.
Because of its depressant CNS effects, patients receiving triazolam should be cautioned
against engaging in hazardous occupations requiring complete mental alertness such as operating
machinery or driving a motor vehicle. For the same reason, patients should be cautioned about the
simultaneous ingestion of alcohol and other CNS depressant drugs during treatment with HALCION Tablets.
As with some but not all benzodiazepines, anterograde amnesia of varying severity and paradoxical reactions have been reported following therapeutic doses of HALCION.
PRECAUTIONS
General: In elderly and/or debilitated patients, it is recommended that treatment with HALCION Tablets be initiated at 0.125 mg. to decrease the possibility of development of oversedation,
dizziness, or impaired coordination.
Some side effects reported in association with the use of HALCION appear to be dose related. These include drowsiness, dizziness, lightheadedness, and amnesia.
The relationship between dose and what may be more serious behavorial phenomena is less
certain. Specifically, some evidence, based on spontaneous marketing reports, suggests that confusion, bizarre or abnormal behavior, agitation and hallucinations may also be dose related, but this
evidence is inconclusive. In accordance with good medical practice it is recommended that therapy
be initiated at the lowest effective dose (See DOSAGE AND ADMINISTRATION).
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Caution should be exercised if HALCION is prescribed to patients with signs or symptoms
of depression which could be intensified by hypnotic drugs. Suicidal tendencies may be present in
such patients and protective measures may be required. Intentional overdosage is more common in
these patients, and the least amount of drug that is feasible should be available to the patient at
any one time.
The usual precautions should be observed in patients with impaired renal or hepatic function
and chronic pulmonary insufficiency.
Information for Patients: To assure safe and effective use of HALCION, the following
information and instructions should be given to patients.
1. Inform your physician about any alcohol consumption and medicine you are taking now, including drugs you may buy without a prescription. Alcohol should generally not be used during
treatment with hypnotics.
2. Inform your physician if you are planning to become pregnant, if you are pregnant, or if you
become pregnant while you are taking this medicine.
3. Inform your physician if you are nursing.
4. Until you experience how this medication affects you, do not drive a car or operate potentially
dangerous machinery, etc.
5. Do not increase prescribed dosage.
6: Patients should also be advised that they may experience an increase in sleep complaints (rebound insomnia) on the first night or two after discontinuing the drug.
Laboratory Tests: Laboratory tests are not ordinarily required in otherwise healthy patients.
Drug Interactions: Both pharmacodynamic and pharmacokinetic interactions have been reported
with benzodiazepines. In particular, triazolam produces additive CNS depressant effects when coadministered with other psychotropic medications, anticonvulsants, antihistamines, ethanol, and
other drugs which themselves produce CNS depression.
Pharmacokinetic interactions can occur when triazolam is administered along with drugs that
interfere with its metabolism. Specific examples, documented with evidence from controlled trials,
show that the co-administration of either cimetidine or erythromycin with triazolam cause an
approximate doubling of the elimination half-life and plasma levels of triazolam. Consequently,
consideration of dose reduction may be appropriate in patients treated concomitantly with either
cimetidine or erythromycin and triazolam.
Carcinogenesis, Mutagenesis, Impairment of Fertility: No evidence of carcinogenic potential
was observed in mice during a 24-month study with HALCION in doses up to 4000 times the
human dose.
Pregnancy:
1. Teratogenic Effects: Pregnancy Category X. See CONTRAINDICATIONS.
2. Non-Teratogenic Effects: It is to be considered that the child born of a mother who is on
benzodiazepines may be at some risk for withdrawal symptoms from the drug, during the postnatal period. Also, neonatal flaccidity has been reported in an infant born of a mother who had been
receiving benzodiazepines.
Nursing Mothers: Human studies have not been performed, however, studies in rats have indicated that HALCION and its metabolites are secreted in milk. Therefore, administration of
HALCION to nursing mothers is not recommended.
Pediatric Use: Safety and efficacy of HALCION in children below the age of 18 have not been
established.

ADVERSE REACTIONS
During placebo-controlled clinical studies in which 1003 patients received HALCION Tablets, the most troublesome side effects were extensions of the pharmacologic activity of triazolam,
eg. drowsiness, dizziness, or lightheadedness.
The figures cited below are estimates of untoward clinical event incidence among subjects
who participated in the relatively short duration (ie. 1 to 42 days) placebo-controlled clinical trials
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of HALCION. The figures cannot be used to predict precisely the incidence of untoward events in
the course of usual medical practice where patient characteristics and other factors often differ
from those in clinical trials. These figures cannot be compared with those obtained from other
clinical studies involving related drug products and placebo as each group of drug trials are conducted under a different set of conditions.
Comparison of the cited figures, however, can provide the prescriber with some basis for
estimating the relative contributions of drug and non-drug factors to the untoward event incidence
rate in the population studied. Even this use must be approached cautiously, as a drug may relieve
a symptom in one patient while inducing it in others. [For example, an anticholinergic, anxiolytic
drug may relieve dry mouth (a sign of anxiety) in some subjects but induce it (an untoward event)
in others.]

Number of Patients

HALCION

Placebo

1003

997

o/o Patients Reporting:

Central Nervous System
14.0

6.4

Headache

9.7

8.4

Dizziness

7.8

3.1

Nervousness

5.2

4.5

Lightheadedness

4.9

0.9

Coordination Disorders/Alaxia

4.6

0.8

4.6

3.7

Drowsiness

Gastrointestinal
Nausea/Vomiting

In addition to the relatively common (ie, 1o/o or greater) untoward events enumerated above,
the following adverse events have been reported less frequently (ie, 0.9-0.5%), euphoria, tachycardia, tiredness, confusional states/memory impairment, cramps/pain, depression, visual
disturbances.
Rare (ie, less than 0.5%) adverse reactions included constipation, taste alterations, diarrhea,
dry mouth, dermatitis/allergy, dreaming/nightmares, insomnia, paresthesia, tinnitus, dysesthesia,
weakness, congestion, death from hepatic failure in a patient also receiving diuretic drugs.
In addition to these untoward events for which estimates of incidence are available, the following adverse events have been reported in association with the use of HALCION and other
benzodiazepines; amnestic symptoms (anterograde amnesia with appropriate or inappropriate behavior), confusional states (disorientation, derealization, depersonalization, and/or clouding of consciousness), dystonia, anorexia, fatigue, sedation, slurred speech, jaundice, pruntus, dysarthria,
changes in libido, menstrual irregularities, incontinence and urinary retention. Other factors may
contribute to some of these reactions, eg, concomitant intake of alcohol or other drugs, sleep deprivation, an abnormal premorbid state, etc.
Other events reported include, paradoxical reactions such as stimulation, an agitational state
(restlessness, irritability and excitation), increased muscle spasticity, sleep disturbances, hallucinations, aggressiveness, falling, somnambulism, inappropraite behavior and other adverse behavioral
effects. Should these occur, use of the drug should be discontinued.
Laboratory analyses were performed on all patients participating in the clinical program for
HALCION. The following incidences of abnormalities were observed in patients receiving HALCION and the corresponding placebo group. None of these changes were considered to be of
physiological significance.

106

B.Y.U. JOURNAL OF PUBLIC LAW

Number of Patients
% of Patients
Reporting
Hematology
Hematocrit
Hemoglobin
Total WBC Count
Neutrophil Count
Lymphocyte Count
Monocyte Count
Eosinophil Count
Basophil Count

[Volume 5

HALCION
380

Low

Low

1.7
1.5
2.3
3.6
10.2
1.7

Placebo

361

2.1
1.5
4.0
3.2
2.1

3.3
3.1
4.4
9.8

1.3
1.0
3.8
1.5
3.4
1.8

Urinalysis
1.1

Albumin
Sugar
RBC/HPF
WBC/HPF

2.9
7.9

2.9
11.7

Blood
Chemistry
Creatinine
Bilirubin
SGOT
Alkaline Phosphatase

2.4

1.9
1.5
5.3
2.2

3.6
1.0

1.5
4.5
2.6

*Less than I%
When treatment with HALCION is protracted, periodic blood counts, urinalysis and blood
chemistry analyses are advisable.
Minor changes in EEG patterns, usually low-voltage fast activity have been observed in patients during therapy with HALCION and are of no known significance.
DRUG ABUSE AND DEPENDENCE
Controlled Substance: Triazolam is a controlled substance under the Controlled Substance Act
and HALCION Tablets have been assigned to Schedule IV.
Abuse and Dependence: Withdrawal symptoms similar in character to those noted with barbiturates and alcohol have occurred following abrupt discontinuance of benzodiazepine drugs. These
can range from mild dysphoria to a major syndrome which may include abdominal and muscle
cramps, vomiting, sweating, tremor, and convulsions.
Patients with a history of seizures should not be abruptly withdrawn from any CNS depressant agent, including HALCION Addiction-prone individuals, such as drug addicts and alcoholics,
should be under careful surveillance when receiving triazolam because of the predisposition of
such patients to habituation and dependence. As with all hypnotics, repeat prescriptions should be
limited to those who are under medical supervision.
OVERDOSAGE
Because of the potency of triazolam, overdosage may occur at 2 mg. four times the maximum
recommended therapeutic dose (0.5 mg).
Manifestations of overdosage with HALCION Tablets include somnolence, confusion, impaired coordination, slurred speech, and, ultimately, coma. As in all cases of drug overdosage,
respiration, pulse, and blood pressure should be monitored and supported by general measures
when necessary. Immediate gastric lavage should be performed. An adequate airway should be
maintained. Intravenous fluids may be administered.
Experiments in animals have indicated that cardiopulmonary collapse can occur with massive
intravenous doses of triazolam (over 100 mg/kg. more than 10,000 times the maximum daily
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human dose). This could be reversed with positive mechanical respiration and the intravenous
infusion of norepinephrine bitartrate or metaraminol bitartrate. Hemodialysis and forced diuresis
are probably of little value. As with the management of intentional overdosage with any drug, the
physician should bear in mind that multiple agents may have been ingested by the patient.
The oral LD 50 in mice is greater than 1000 mg/kg and in rats is greater than 5000 mg/kg.
DOSAGE AND ADMINISTRATION
It is important to individualize the dosage of HALCION Tablets for maximum beneficial
effect and to help avoid significant adverse effects.
The recommended dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg may be
found to be sufficient for selected patients. A dose of 0.5 mg shold be reserved for those patients
who do not respond adequately to a lower dose since the risk of several adverse reactions increases
with the size of the dose administered.
In geriatric and/or debilitated patients, the recommended dosage range is 0.125 mg to 0.25
mg. Therapy should be initiated at 0.125 mg in this group.
As with all medications, the lowest effective dose should be used.
HOW SUPPLIED
HALCION Tablets are available in the following strengths and package sizes:
0.125 mg (pale lavender):
Bottles of 100
NDC 0009-0010-01
Unit Dose Pkg. (100)
NDC 0009-0010-22
VISIPAK® Reverse Numbered Pack (100)
NDC 0009-0010-04
Bottles of 500
NDC 0009-0010-11
0.25 mg (powder blue, scored)
Bottles of 100
NDC 0009-0017-01
Unit Dose Pkg (100)
NDC 0009-0017-08
VISIPAK Reverse Numbered Pack (100)
NDC 0009-0017-17
Bottles of 500
NDC 0009-0017-02
Store at controlled room temperature 15°-30° C (59°-86° F).
Caution: Federal law prohibits dispensing without prescription.
US Patent No. 3,987,052
The Upjohn Company
Kalamazoo, Michigan 49001, USA
Revised April 1989

812 110 217
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February 24, 1989
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John Sias, President
Capital Cities' ABC. I.c.c.
1330 Avenue of the Americas
New York, New York 10019
Dear Mr. Sias:
As president az1d chief operating officer of the The UpjohJl Compaz1y. I am
responding to the February 17 broadcast of a segment of"20/20" that
concerned HALCION Tablets. az1 Upjohll product. After careful medical.
scientific and legal az1alysis of the broadcast. it is our opinion that the
segment on Halcion was misleading az1d contained unfounded allegations
ud substantial misrepresentations. My intent in writing is to clariiy our
concerns.
"20/20" focused a large segment of the broadcast on the case of Mrs. llo
Grundberg of Utah. From our ualysis of"20/20" az1d related newspaper
clippings, Mrs. Grundberg was not following the- package insert
recommendations. The reporter. Stone Phillips. clearly stated that not oaiy
was Mrs. Grundberg using the drug to excess. but she also was t.a.kiag it
nearly every night for fourteen months. both of wttich are coc..sidereci
inappropriate use. However, "20/20" concluded in its broadcast that
Halcion was to blame for the murder of Mrs. Grundberg's mother. " ... (H)ad
it not been for the Halcion, she would not have killed her mother." This is
simply not true. "20120" made no mention of Mrs. Grundberg's medical
history or her concomitazlt use of other medications. However, in other
media reports of her case it was clearly indicated that she was also taking
diazepam and was sutl"ering from depression. The package insert states
"caution should be exercised ifHalcion is prescribed to patients with signs
or symptoms of depression wilich could be intensified by ilypnotic drugs.··
The pac.ltage insert also cautions against the simultaneous ingestion of
other psychotropic medications.
Furthermore. "20/20" misrepresented the ruling in the Grundberg case
wttich was not that Halcion caused her to do wilat she did. but that her
judgment was impaired at the time of her mother's murder for a varietv of
reasons. To ignore these other reasons az1d focus on Halcion alone.
concluding it was the "real" reason for the criminal activity is irresponsible
and doe-s a great disservice to the millions of patients and their physicians
who have successfully used Halcion.
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Jolul Sia.s. President
Page -2February 24. 1989
The second anecdotal experience focused on wa.s the case of Steve McCoy. Upon
close examinauon of the records included in your stDry, it appears there were
some discrepiUlcies between the visualiUld verbal accounts of McCoy's
situation. Namely, a psychological evaluation on May l. 1987 reportedly gave
McCoy a clean bill of health immediately prior tD his taking Halcion. The
~20120~ report stated that a year after using Halcion he was diagnosed as
suffering from a major depression with psychosis. Yet, the date on the
admittance form presented during the broadcast shows McCoy's diagnosis of
depression with psychosis appearing tD be August 26, 1987. This obviously is
not one year aft.er the original diagnosis of his mental health status IUld it also
falls before the stock market crash in October 1987, which "20/20~ capitali%ed
on IUld dramatically recreated in its broadcast.
The enensive warnings on Halcion claimed by "20/20" to be required by the
Food IUld Drug Administration were inaccurate. Nowhere in the package
insert does it state that therapy should be no longer than 14 days. The label's
actual wording is. "it is recommended that Halcion not be prescribed in
quiUltities exceeding a one-month supply.~ Because Halcion is indicated for
short-term or transient insomnia, Upjolul includes this recommendation to
physicia.ns to encourage patient reevaluation on a periodic basis tD determine if
the medication is still needed.
"20120~ seemed to try tD sensationali:e the fact that depression, a.zuiety IUld
memory loss have been reported with the use ofHalcion. when the reality is
that these side effects have been reported with ben%odiazepines in geo.eral. It
must also be noted that such side effects are unusual. occuring in less than l
percent of patients in controlled clio.ic:a.l trials.

The package insert for Halcion states that "the recommended dose for most
adults is 0.25 mg before retiring....A dose of0.5 mg should be reserved for those
patients who do not respond adequately tD a lower dose since the risk of several
adve~ reactions increases with the site of the dose administered. In geriatric
and/or debilitated patients, the recommended dosage range is 0.125 mg to 0.25
mg. Therapy should be initiated at 0.1.25 mg in this group." While the
majority of patients are effectively treated with the 0..25 mg dose, some patients
because of site. age and other factors are not responsive to this dosage strength
and req_uire 0.5 mg. While the 0.5 mg tablet is no longer produced, the dosage
strengt.11 remains a valuable option for therapy-resistant patients. You claim
that recommending the 0.5 mg dosage is "defeating the whole purpose of
removing the .5 mg tablets in the first place.~ The Upjohn Company disagrees.
The purpose for discontinuing the 0.5 mg tablet strength was an additional
effort to emphasize usage of the lowest effective dose and as a result of the
worldwide trend toward. decreased prescribing and usage of the 0.5 mg tablet.
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John Sias. President
Pa~e .J.
February 24. 1989
The discontinuation of the 0.5 mg tablet is consistent with medical evidence
developed over a number of years regarding the use of Halcion and other
bell%0diuepines: 1.) therapy should be initiated at the lowest effective dose
and 2.) some adverse events may be dose related. Side effects of the
bell%0diuepines that are related to their pharmacologic activity, e.g.
drowsiness. lightheaded.ness, amnesia and dizziness. are dose related. The
relation.sh.i p of dose with the risk of other adverse reactions is less obvious. By
emphasizing the lower dosages of Halcion, introducing a 0.125 tablet strength
and revising the product labeling to reflect a starting dose of 0.25 mg, U pjohn
continues to encourage the safest dose possible while maintaining efficacy.
However, Upjohn maintains that tailoring the dosage to the individual is
essential, and for those patients that do not respond to 0.25 mg, the 0.5 mg
dosage remains a.n important therapeutic option.
Ofutm.ost conceru to me was a statement that Upjoh.n refused to speak with
R20/20." This is patently untrue. We did decline to provide an on-camera
interview, but we spoke long and often with your producer, providing a great
deal of background information a.nd offering additional assistance during
several phone conversations. We also provided a written statement to R20/20. R
Refusing to speak implies total silence a.nd carries a.n undesirable implication
that clearly misrepresents Upjoh.n's position, which is that the entertainment
program "20/20" was far more interested in sensationalizing the anecdotal
reports of a few, selected individuals rather than providing a balanced story
based on medical and scientific fact.
Dr. Martin Scharf, a known opponent ofHalcion, stated that he has '1lad
instances of people who have either attempted murder or literally committed
murder claiming to be under the influence of the medication. R The key phrase
is "claiming to be under the influenceR ofHalcion. By using the word
Rclaiming," no verification is established whether or not the drug was actually
involved. a.nd by stating the individual was "under the influence" provides no
clear causal relationship. Also. no clarification was made whether or not those
persons were alto under the influence of alcohol, had a history of depression or
psychotic beha'rior or whether other medications were involved. lD other
words, the viewers only saw part of the picture.
As reporter Stone Phillips dramatically fanned a computer printout of adverse
reactions 011 screen a.nd claimed they were related to Balcion, 110 mention was
made that the FDA explicitly states that such voluntary reports c:a.n.not be used
to estimate incidence of adverse react:i.ona. The FDA letter that accompanies
the printout oC spontaneously reported data states: --rile information contained
in the reports is considered raw illformation and hu not been verified as to a
cause a.nd eft'ectrelation.sh.ip. This information cannot be used to estimate the
incidence of adverse drug reactions." There are Dumerous factors aft'ecti.ng the
Spontaneous Reporting System of the FDA's Division ofDruc and Biological
Produce Experience. Among them are the reporting practices of each
manufacturer. This is particularly significant because approzim.ately 80
percent of such reports come to the system directly from m&.Dufacturers. Most
of the triamlam reports in the FDA data base originated with The U pjoh.n
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Company. It is well known. and acknowledged by the FDA. that The Upjohn
Company has one of the most thorough systems in the industry for reporting
medical events associated with their products. "20/20's" editorial treatment of
this makes the company's diligence seem proof of a problem with Halcion.
wbich it is not.
Mention was made in the program that "Dutch authorities pulled (Halcionl off
the market after a rash of complaints about the drug's side effects." Although
U pjohn provided "20120" with an accurate and complete account of the events
in Holland. you decided to focus on only the most sensational aspect of the
situation and tell half the story.
For the record, in August 1979 the Dutch Registration College imposed a
temporary six-month withdrawal of the product license for Halcion 0.25 mg
ed 0.5 mg tablets in Holland.. The college's action followed intense public
pressure, after allegations of unusual side effects associated with the use of the
product were reported by a single Dutch psychiatrist.
In February 1980 the college announced that the license for 0.25 mg Halcion
tablets could be reinstated ifUpjohn would agree to include in its labeling a list
of possible and unusual side effects. Upjohn refused to accept these conditions
because they were UDSUbstantiated in world medical literature, in extensive
clinical tests and in our worldwide experience with the product. (Paltes. G.E.
"Triuolam; A Review of its Pharmacological Properties and Therapeutic
Efficacy in Patients with Insomnia." Drugs 22: 104-105, 1981.)

Subsequently the Registration College cancelled the product license for 0.25
mg and 0.5 mg Halcion tablets. Upjohn filed an appeal with the Dutch Council
of State in 1980. arguing that the college's decision was not based on scientific
evidence.
On the recommendation of the Dutch Council of State, the Crown decided in
June 1985 to cancel the decision made by the Registntion College in February
1980. ID arriving at this conclusion. the Crown held that the Dutch
Registration College acted without adequate review of available data. and did
not o'--"e sufficient diligence when it cancelled the registration ofHalcion.
The council also considered. however, that the 1977 pacltage insert for Halcion
in Holland could not be reinstated without amendment in light of subsequent
worldwide experience with bea.zndiuepines and product registntions since
1980. The Council sugested that Upjohn apply for a new product license for
Halcion in Holland through the Recmration College. Obviously the issue did
not end with the Dutch govenunent pulling the product off the market. as was
stated in your broadcast.
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Another sensationalized statement involved Halcion being among the top
twenty drugs cited in emergency room cases. To put this information in the
proper conten.it would be appropriate to mention that aspirin. acetaminophen
and alcohol in combination with other drugs ra.nk higher than Halcion in the
listing. Most importantly, the Drug Abuse Warning Network IDA WN), which
publishes the data. makes no attempt to !lualify the raw data. In other wonis.
no cause-and-effect relationship is established between the drug and the reason
for the emergency room visit. As an ez:ample, if a person attempted suicide by
ingesting drain cleBller and was brought in to a hospital. traces of any
medication in that person would be recorded in the DAWN data.
You also indicated that the FDA acknowledged receiving more complaints
about Halcion than other sleeping pills. Was this put in the context that
Halcion is by far the most prescribed hypnotic and that one would expect to
receive more reports on a drug that is used sigu.ifiC8lltly more than the others?
It was not.
The safe and effective use of any medication involves at least three clear
responsibilities. A pharmaceutical company must resea.n:h.. test. report on and
manufacture safe medicines. Physicians are responsible for properly
diagnosing health problems and. if deemed effective therapy, prescribing
medications and discussing them with the patient. Patients are responsible for
properly using medications according to physician directions.
When properly produced. prescribed and used. Halcion Tablets provide safe and
effective treatment for short-term insom.niL This has been well documented in
numerous clinical studies and well established in more than 10 years of general
medical use.
Halcion represents a significant advance in safety over earlier agents. wb.ich
were tozic. interfered with the effects of other medicines and carried a b.igh
potential for facilitating suicide. In 1984, the United States National Institute
of Mental Health issued a "Consensus Summary on Drugs and Insom.niL" It
2resents the conclusions of a panel of U.S. medical and scientific experts (ana
European observers) brought together to summarize ad.vanced thinking about
the proper treatment of insomnia.
In cues where medication is appropriate for sleep management.. the report
notes. ben:odiazepi.aes are ~:::nble, and for short-term use the smallest
effective dose of a rapidly e · · ated hypnotic, like Halcion, should be used.
The A.merica.a Medical Association cites ben:odiazepines as "the drugs of
choice when an anti1Ul%eity, sedative, or hypnotic action is needed."
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Sleep disturba.c.c= are very real medical problems. Oae-third of the U.S.
populaaon swiers from some degree of in.som:Ua a.c.d 17 percent of them
con.side.r it severe. The consequences of insomnia include impaired daytime
functioning, an%iety a.c.d emoaoaal a.c.d behavioral disturbances amoag others.
Lack of sleep a.c.d sleep-related fact.ors appear involved iD. such catastrooi:Uc:
disasters u the Che.rnobyl auclear disaster, Three Mile Isla.c.d a.c.d the $pac:e
Shuttle Challenger accident. (Mitler, M. et aL "Catast:z"Ophes, Sleep a.c.d Public:
Policy: C~ Report." Slap 11:1, 1988, pp.100-l08.l
Ralcion is a.c. important therapeutic: agent for the treatment of short-term and
lnn.sient iDsoamiL When prescribed a.c.d used appropriately, it is effective
and has a hiP.IJlUiill of safety. Foc:usi.ng on the anecdotalac:counts of unusual
a.c.d severe Slde effects does a great disse.r"''ice to the millioas of patients who
are or have been treated suc:cessfully with this medication.
Upjohn has acted responsibly in researdl.ing, developing, marketing and
report:i.ng on Halcion. We are held accountable for what we do by the FDA. by
doctors and by paaents. We take these respoasibiliaes very seriously.
SiD.cerely,

~~~4-!1
LaW"!'ellc:tl C. HoB' . v
The Gpjonn Company .

!l

114

B.Y.U. JOURNAL OF PUBLIC LAW
APPENDIX

[Volume 5

C

Seec:nam
taborat:ortes
February 6, 1990
Dear Pharmacist:
From all accounts, this year's respiratory infection season may be one of the
most active on record. Therefore. the number of prescriptions written for
AMOXILI will be higher than ever. To make sure your inventories of AMOXIL are
adequate for this increased demand, Beecham Laboratories would like to rem~nd
you of the exclusive reorder privileges you have qualified for.
By EJurchasing last year's Oral Antibiotlc Offer, you are eligible for both
free goods and extended dating on all reorders for AMOXIL.
Free Gooda
:'o qualify for AMOXIL free goods, you need to order seven bottles, or any
combination of seven bottles, of the same oackaae size ( 100s or SODs) in
Alo!OXIL Capsules to receive one bottle of AMOXIL Capsules in the lesser
strength free. You need to order 24 bott~es of AMOXIL Oral Suspension in the
same package size to receive one bottle of AMOXIL ~ral Suspens~on free.
Examples:

If you order seven bottles of AMOXIL 250 mg or 500 mg Capsules, you
rece~ve one free bottle of
~~OXIL Capsules in that same strengtn and package size.

·.,ill be invoiced for six bottles and

:f you order four bottles of 250 mg A SOD AMOXIL Capsules and :hree
bottles of 500 mg x 500 AMOXIL Capsules or any combination total~nq
seven, you will be invoiced for a total of six bottles and rece1ve
one free bottle of 2SO mg x SOD AMOXIL Capsules.
Extended Datinc;
All reorders will receive a 2 percent discount, 90 days, net 91 days dating.
To reorder, please contact your Beecham Sales
1-800-251-7040 (1-800-821-0279 Tennessee only).
'l'hil uc:lulive reorder

pn~qra

Representative

or

phone

encla March 31, 1990.

Beecham will continue to maintain your trust by offer1nq you quality products
at competitive prices and providing you with outstand1ng serv1ce.
Thank you for your support and confidence in Beecham.
Sincerely,

?~"VA
~tM-14Edwin M. Christensen
Vice President, Sales
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§ 4.2.8 Phaf'11UJ£eulit:al Manv.ftKturns ...t.uociatioft CotU of Fair
Praetit:a in th. Promotion of Drug Protlut:t.r*

Recognizing the importance to the public health of providing the
medical profession with accurate information on drug products,
and the need to assure that PMA members, their employees and
agents present such information fairly and objectively.
The Pharmaceutical Manufacturers Association hereby
promulgates and adopts the following Code of Fair Practices in the
Promotion of Drug Products as a revision of its 1958 Statement of
Principles on the same subject:
A. Code Standards
1. As used in this Code:
(a) The term "drug product" means any pharmaceutical or
biological product intended for use in the diagnosis, cure,
mitigation, treatment or prevention of disease in humans,
or to affect the structure or any function of the human
body, which is promoted and advertised to the medical
profession rather than directly to the lay public.
(b) The term "promotional communications" means ( 1)
journal advertising, mailing pieces, and similar written
materials (including, to the extent reasonably prac·
ticable, films, exhibits and similar visual presentations)
directed to members of the medical profession by the
pharmaceutical industry for the purpose of promoting a
drug product and (2) written instructions and materials
prepared for sales or professional representatives con·
taining representations to be made by them to members
of the medical profession. Where compliance with the
requirements of this Code is not reasonably practicable
within the format of a film, exhibit or similar visual pre·
sentation, written materials meeting those requirememts
shall be distributed to all members of the medical
profession attending the presentation.
(c) The term "medical profession" includes allied professions
in the health field.

'These standards are dated September 1967 and are believed by the editor to
be current.
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2. Complete and accurate information concerning marketed

drug products should be made available promptly to the
medical profession. Promotional communications to the
medical profession which include a description of indicated
uses or dosage recommendations for a prescription drug
product should also include a summary (or full disclosure
where required by law) of side effects, precautions, warnings
and contraindications, and of effectiveness for the described
indicated uses. Such summary should have sufficient
prominence in terms of type size, location and similar factors
to provide reasonable assurance that it will be observed.
3.Statements in promotional communications should be based
upon substantial scientific evidence or other responsible
medical opinion. Claims should not be stronger than such
evidence warrants. Every effort should be made to avoid
ambiguity. Whenever statistical or background information
or references to unpublished literature or observations are
used in promotional communications, the source material ·
should be available to the medical profession upon request.
4.Statements with respect to or quotations from medical
literature or from the personal communications of clinical
investigators in promotional communications should not
distort the intended meaning of the author or the
significance of the study.
s.Any comparison with other drug products should be made
upon a valid scientific basis.
&.No public communication by a manufacturer shall be
made with the intent of promoting a drug product as safe
and effective for any use before the required approval of
the drug product for marketing for such use is obtained.
However, this provision is not intended to abridge the right
of the scientific community and the public to be fully
informed concerning scientific and medical progress. Thus
it is not intended to restrict a full and proper exchange of
;cientific information concerning a drug product, including
appropriate dissemination of investigational findings in
;cientific or lay communications media, nor to restrict
public disclosure to stockholders and others concerning any

69]

THE HALCION HOMICIDE

117

drug product as may be required or desirable under law,
rule or regulation.
7. Promotional communications should have medical
clearance before their release.
B. Code Administration
It is the unqualified intent of the Association that each
member shall follow strictly the principles set forth in the
Code. To that end the members of the PMA are encouraged
to submit information to the President with respect to any
alleged breach of this Code by any other member. On the
basis of such information and any other information available
to him, the President shall take appropriate action including.
if required, referral of the information to an ad hoc com·
mittee of the Buard. The committee shall be chosen by the
Chairman of the Board unless the member company
represented by the Chairman has submitted such information
or is the subject of such information, in which case the
President shall make the appointments: The General Co~nsel
of the Association shall act as secretary of each ad hoc
committee and shall report the committee's findings to the
89
President who in turn will refer the findings to the Board of
Directors.
Any member firm which clearly and persistently violates the
Code may be asked by the Board of Directors to resign from
the Association.

